id sid tid token lemma pos work_ksthdbpq7vbwdm3jhrt2dav524 1 1 Sunitinib Sunitinib NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 2 Plus Plus NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 3 Paclitaxel Paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 4 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 1 5 Patients Patients NNPS work_ksthdbpq7vbwdm3jhrt2dav524 1 6 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 1 7 Advanced Advanced NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 8 Esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 1 9 Cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 1 10 : : : work_ksthdbpq7vbwdm3jhrt2dav524 1 11 A a DT work_ksthdbpq7vbwdm3jhrt2dav524 1 12 Phase Phase NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 13 II II NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 14 Study study NN work_ksthdbpq7vbwdm3jhrt2dav524 1 15 from from IN work_ksthdbpq7vbwdm3jhrt2dav524 1 16 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 1 17 Hoosier Hoosier NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 18 Oncology Oncology NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 19 Groupe Groupe NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 20 760 760 CD work_ksthdbpq7vbwdm3jhrt2dav524 1 21 Journal Journal NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 22 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 1 23 Thoracic Thoracic NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 24 Oncology Oncology NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 25 • • NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 26 Volume volume NN work_ksthdbpq7vbwdm3jhrt2dav524 1 27 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 1 28 , , , work_ksthdbpq7vbwdm3jhrt2dav524 1 29 Number number NN work_ksthdbpq7vbwdm3jhrt2dav524 1 30 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 1 31 , , , work_ksthdbpq7vbwdm3jhrt2dav524 1 32 April April NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 33 2012 2012 CD work_ksthdbpq7vbwdm3jhrt2dav524 1 34 BRIEF BRIEF NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 35 REPoRT REPoRT NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 36 Abstract Abstract NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 37 : : : work_ksthdbpq7vbwdm3jhrt2dav524 1 38 The the DT work_ksthdbpq7vbwdm3jhrt2dav524 1 39 combination combination NN work_ksthdbpq7vbwdm3jhrt2dav524 1 40 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 1 41 sunitinb sunitinb NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 42 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 1 43 37.5 37.5 CD work_ksthdbpq7vbwdm3jhrt2dav524 1 44 mg mg NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 45 orally orally RB work_ksthdbpq7vbwdm3jhrt2dav524 1 46 daily daily JJ work_ksthdbpq7vbwdm3jhrt2dav524 1 47 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 1 48 + + NFP work_ksthdbpq7vbwdm3jhrt2dav524 1 49 pacli- pacli- NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 50 taxel taxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 51 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 1 52 90 90 CD work_ksthdbpq7vbwdm3jhrt2dav524 1 53 mg mg CD work_ksthdbpq7vbwdm3jhrt2dav524 1 54 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 1 55 m2 m2 NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 56 intravenously intravenously RB work_ksthdbpq7vbwdm3jhrt2dav524 1 57 on on IN work_ksthdbpq7vbwdm3jhrt2dav524 1 58 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 1 59 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 1 60 , , , work_ksthdbpq7vbwdm3jhrt2dav524 1 61 8 8 CD work_ksthdbpq7vbwdm3jhrt2dav524 1 62 , , , work_ksthdbpq7vbwdm3jhrt2dav524 1 63 15 15 CD work_ksthdbpq7vbwdm3jhrt2dav524 1 64 every every DT work_ksthdbpq7vbwdm3jhrt2dav524 1 65 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 1 66 weeks week NNS work_ksthdbpq7vbwdm3jhrt2dav524 1 67 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 1 68 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 1 69 examined examine VBN work_ksthdbpq7vbwdm3jhrt2dav524 1 70 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 1 71 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 1 72 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 1 73 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 1 74 esophageal esophageal NN work_ksthdbpq7vbwdm3jhrt2dav524 1 75 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 1 76 gastroesophageal gastroesophageal NN work_ksthdbpq7vbwdm3jhrt2dav524 1 77 junction junction NN work_ksthdbpq7vbwdm3jhrt2dav524 1 78 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 1 79 , , , work_ksthdbpq7vbwdm3jhrt2dav524 1 80 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 1 81 progression progression NN work_ksthdbpq7vbwdm3jhrt2dav524 1 82 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 1 83 free free JJ work_ksthdbpq7vbwdm3jhrt2dav524 1 84 survival survival NN work_ksthdbpq7vbwdm3jhrt2dav524 1 85 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 1 86 PFS PFS NNP work_ksthdbpq7vbwdm3jhrt2dav524 1 87 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 1 88 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 1 89 compared compare VBN work_ksthdbpq7vbwdm3jhrt2dav524 1 90 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 1 91 that that DT work_ksthdbpq7vbwdm3jhrt2dav524 1 92 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 1 93 historical historical JJ work_ksthdbpq7vbwdm3jhrt2dav524 1 94 controls control NNS work_ksthdbpq7vbwdm3jhrt2dav524 1 95 . . . work_ksthdbpq7vbwdm3jhrt2dav524 2 1 The the DT work_ksthdbpq7vbwdm3jhrt2dav524 2 2 end end NN work_ksthdbpq7vbwdm3jhrt2dav524 2 3 points point NNS work_ksthdbpq7vbwdm3jhrt2dav524 2 4 included include VBD work_ksthdbpq7vbwdm3jhrt2dav524 2 5 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 2 6 rate rate NN work_ksthdbpq7vbwdm3jhrt2dav524 2 7 , , , work_ksthdbpq7vbwdm3jhrt2dav524 2 8 overall overall JJ work_ksthdbpq7vbwdm3jhrt2dav524 2 9 survival survival NN work_ksthdbpq7vbwdm3jhrt2dav524 2 10 , , , work_ksthdbpq7vbwdm3jhrt2dav524 2 11 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 2 12 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 2 13 . . . work_ksthdbpq7vbwdm3jhrt2dav524 3 1 Twenty twenty CD work_ksthdbpq7vbwdm3jhrt2dav524 3 2 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 3 3 eight eight CD work_ksthdbpq7vbwdm3jhrt2dav524 3 4 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 3 5 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 3 6 enrolled enrol VBN work_ksthdbpq7vbwdm3jhrt2dav524 3 7 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 3 8 six six CD work_ksthdbpq7vbwdm3jhrt2dav524 3 9 centers center NNS work_ksthdbpq7vbwdm3jhrt2dav524 3 10 . . . work_ksthdbpq7vbwdm3jhrt2dav524 4 1 Median median JJ work_ksthdbpq7vbwdm3jhrt2dav524 4 2 age age NN work_ksthdbpq7vbwdm3jhrt2dav524 4 3 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 4 4 59.5 59.5 CD work_ksthdbpq7vbwdm3jhrt2dav524 4 5 years year NNS work_ksthdbpq7vbwdm3jhrt2dav524 4 6 . . . work_ksthdbpq7vbwdm3jhrt2dav524 5 1 The the DT work_ksthdbpq7vbwdm3jhrt2dav524 5 2 24-week 24-week CD work_ksthdbpq7vbwdm3jhrt2dav524 5 3 PFS PFS NNP work_ksthdbpq7vbwdm3jhrt2dav524 5 4 rate rate NN work_ksthdbpq7vbwdm3jhrt2dav524 5 5 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 5 6 25 25 CD work_ksthdbpq7vbwdm3jhrt2dav524 5 7 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 5 8 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 5 9 90 90 CD work_ksthdbpq7vbwdm3jhrt2dav524 5 10 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 5 11 confidence confidence NN work_ksthdbpq7vbwdm3jhrt2dav524 5 12 interval interval NN work_ksthdbpq7vbwdm3jhrt2dav524 5 13 [ [ -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 5 14 CI CI NNP work_ksthdbpq7vbwdm3jhrt2dav524 5 15 ] ] -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 5 16 , , , work_ksthdbpq7vbwdm3jhrt2dav524 5 17 12–42 12–42 CD work_ksthdbpq7vbwdm3jhrt2dav524 5 18 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 5 19 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 5 20 . . . work_ksthdbpq7vbwdm3jhrt2dav524 6 1 Three three CD work_ksthdbpq7vbwdm3jhrt2dav524 6 2 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 6 3 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 6 4 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 6 5 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 6 6 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 6 7 23 23 CD work_ksthdbpq7vbwdm3jhrt2dav524 6 8 evaluable evaluable JJ work_ksthdbpq7vbwdm3jhrt2dav524 6 9 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 6 10 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 6 11 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 6 12 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 6 13 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 6 14 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 6 15 complete complete JJ work_ksthdbpq7vbwdm3jhrt2dav524 6 16 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 6 17 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 6 18 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 6 19 partial partial JJ work_ksthdbpq7vbwdm3jhrt2dav524 6 20 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 6 21 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 6 22 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 6 23 90 90 CD work_ksthdbpq7vbwdm3jhrt2dav524 6 24 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 6 25 CI ci NN work_ksthdbpq7vbwdm3jhrt2dav524 6 26 , , , work_ksthdbpq7vbwdm3jhrt2dav524 6 27 3−25 3−25 CD work_ksthdbpq7vbwdm3jhrt2dav524 6 28 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 6 29 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 6 30 . . . work_ksthdbpq7vbwdm3jhrt2dav524 7 1 Median median JJ work_ksthdbpq7vbwdm3jhrt2dav524 7 2 overall overall JJ work_ksthdbpq7vbwdm3jhrt2dav524 7 3 survival survival NN work_ksthdbpq7vbwdm3jhrt2dav524 7 4 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 7 5 228 228 CD work_ksthdbpq7vbwdm3jhrt2dav524 7 6 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 7 7 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 7 8 90 90 CD work_ksthdbpq7vbwdm3jhrt2dav524 7 9 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 7 10 CI CI NNP work_ksthdbpq7vbwdm3jhrt2dav524 7 11 , , , work_ksthdbpq7vbwdm3jhrt2dav524 7 12 140–283 140–283 CD work_ksthdbpq7vbwdm3jhrt2dav524 7 13 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 7 14 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 7 15 . . . work_ksthdbpq7vbwdm3jhrt2dav524 8 1 Grade Grade NNP work_ksthdbpq7vbwdm3jhrt2dav524 8 2 3/4 3/4 CD work_ksthdbpq7vbwdm3jhrt2dav524 8 3 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 8 4 included include VBD work_ksthdbpq7vbwdm3jhrt2dav524 8 5 leukopenia/ leukopenia/ NNP work_ksthdbpq7vbwdm3jhrt2dav524 8 6 neutropenia neutropenia NNP work_ksthdbpq7vbwdm3jhrt2dav524 8 7 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 8 8 25 25 CD work_ksthdbpq7vbwdm3jhrt2dav524 8 9 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 8 10 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 8 11 , , , work_ksthdbpq7vbwdm3jhrt2dav524 8 12 anemia anemia NN work_ksthdbpq7vbwdm3jhrt2dav524 8 13 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 8 14 18 18 CD work_ksthdbpq7vbwdm3jhrt2dav524 8 15 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 8 16 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 8 17 , , , work_ksthdbpq7vbwdm3jhrt2dav524 8 18 fatigue fatigue NN work_ksthdbpq7vbwdm3jhrt2dav524 8 19 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 8 20 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 8 21 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 8 22 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 8 23 , , , work_ksthdbpq7vbwdm3jhrt2dav524 8 24 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 8 25 hemorrhage hemorrhage NN work_ksthdbpq7vbwdm3jhrt2dav524 8 26 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 8 27 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 8 28 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 8 29 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 8 30 . . . work_ksthdbpq7vbwdm3jhrt2dav524 9 1 There there EX work_ksthdbpq7vbwdm3jhrt2dav524 9 2 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 9 3 four four CD work_ksthdbpq7vbwdm3jhrt2dav524 9 4 grade grade NN work_ksthdbpq7vbwdm3jhrt2dav524 9 5 5 5 CD work_ksthdbpq7vbwdm3jhrt2dav524 9 6 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 9 7 including include VBG work_ksthdbpq7vbwdm3jhrt2dav524 9 8 upper upper JJ work_ksthdbpq7vbwdm3jhrt2dav524 9 9 gastroin- gastroin- JJ work_ksthdbpq7vbwdm3jhrt2dav524 9 10 testinal testinal JJ work_ksthdbpq7vbwdm3jhrt2dav524 9 11 hemorrhage hemorrhage NN work_ksthdbpq7vbwdm3jhrt2dav524 9 12 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 9 13 n n NNP work_ksthdbpq7vbwdm3jhrt2dav524 9 14 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 9 15 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 9 16 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 9 17 , , , work_ksthdbpq7vbwdm3jhrt2dav524 9 18 gastrointestinal gastrointestinal JJ work_ksthdbpq7vbwdm3jhrt2dav524 9 19 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 9 20 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 9 21 fistula fistula NNP work_ksthdbpq7vbwdm3jhrt2dav524 9 22 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 9 23 n n NN work_ksthdbpq7vbwdm3jhrt2dav524 9 24 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 9 25 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 9 26 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 9 27 , , , work_ksthdbpq7vbwdm3jhrt2dav524 9 28 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 9 29 unexplained unexplained JJ work_ksthdbpq7vbwdm3jhrt2dav524 9 30 death death NN work_ksthdbpq7vbwdm3jhrt2dav524 9 31 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 9 32 n n NNP work_ksthdbpq7vbwdm3jhrt2dav524 9 33 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 9 34 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 9 35 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 9 36 . . . work_ksthdbpq7vbwdm3jhrt2dav524 10 1 In in IN work_ksthdbpq7vbwdm3jhrt2dav524 10 2 our -PRON- PRP$ work_ksthdbpq7vbwdm3jhrt2dav524 10 3 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 10 4 , , , work_ksthdbpq7vbwdm3jhrt2dav524 10 5 we -PRON- PRP work_ksthdbpq7vbwdm3jhrt2dav524 10 6 found find VBD work_ksthdbpq7vbwdm3jhrt2dav524 10 7 that that IN work_ksthdbpq7vbwdm3jhrt2dav524 10 8 suni- suni- XX work_ksthdbpq7vbwdm3jhrt2dav524 10 9 tinib tinib NNP work_ksthdbpq7vbwdm3jhrt2dav524 10 10 + + CC work_ksthdbpq7vbwdm3jhrt2dav524 10 11 paclitaxel paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 10 12 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 10 13 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 10 14 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 10 15 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 10 16 esophageal esophageal NN work_ksthdbpq7vbwdm3jhrt2dav524 10 17 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 10 18 gastroe- gastroe- NN work_ksthdbpq7vbwdm3jhrt2dav524 10 19 sophageal sophageal NN work_ksthdbpq7vbwdm3jhrt2dav524 10 20 junction junction NN work_ksthdbpq7vbwdm3jhrt2dav524 10 21 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 10 22 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 10 23 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 10 24 24-week 24-week CD work_ksthdbpq7vbwdm3jhrt2dav524 10 25 PFS PFS NNP work_ksthdbpq7vbwdm3jhrt2dav524 10 26 no no RB work_ksthdbpq7vbwdm3jhrt2dav524 10 27 better better RB work_ksthdbpq7vbwdm3jhrt2dav524 10 28 than than IN work_ksthdbpq7vbwdm3jhrt2dav524 10 29 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 10 30 PFS PFS NNP work_ksthdbpq7vbwdm3jhrt2dav524 10 31 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 10 32 historical historical JJ work_ksthdbpq7vbwdm3jhrt2dav524 10 33 controls control NNS work_ksthdbpq7vbwdm3jhrt2dav524 10 34 . . . work_ksthdbpq7vbwdm3jhrt2dav524 11 1 The the DT work_ksthdbpq7vbwdm3jhrt2dav524 11 2 combination combination NN work_ksthdbpq7vbwdm3jhrt2dav524 11 3 also also RB work_ksthdbpq7vbwdm3jhrt2dav524 11 4 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 11 5 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 11 6 high high JJ work_ksthdbpq7vbwdm3jhrt2dav524 11 7 rate rate NN work_ksthdbpq7vbwdm3jhrt2dav524 11 8 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 11 9 serious serious JJ work_ksthdbpq7vbwdm3jhrt2dav524 11 10 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 11 11 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 11 12 will will MD work_ksthdbpq7vbwdm3jhrt2dav524 11 13 not not RB work_ksthdbpq7vbwdm3jhrt2dav524 11 14 be be VB work_ksthdbpq7vbwdm3jhrt2dav524 11 15 pursued pursue VBN work_ksthdbpq7vbwdm3jhrt2dav524 11 16 . . . work_ksthdbpq7vbwdm3jhrt2dav524 12 1 Key key JJ work_ksthdbpq7vbwdm3jhrt2dav524 12 2 Words word NNS work_ksthdbpq7vbwdm3jhrt2dav524 12 3 : : : work_ksthdbpq7vbwdm3jhrt2dav524 12 4 Sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 12 5 , , , work_ksthdbpq7vbwdm3jhrt2dav524 12 6 Paclitaxel Paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 12 7 , , , work_ksthdbpq7vbwdm3jhrt2dav524 12 8 Esophageal Esophageal NNP work_ksthdbpq7vbwdm3jhrt2dav524 12 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 12 10 Gastroesophageal Gastroesophageal NNP work_ksthdbpq7vbwdm3jhrt2dav524 12 11 junction junction NN work_ksthdbpq7vbwdm3jhrt2dav524 12 12 , , , work_ksthdbpq7vbwdm3jhrt2dav524 12 13 Angiogenesis Angiogenesis NNP work_ksthdbpq7vbwdm3jhrt2dav524 12 14 , , , work_ksthdbpq7vbwdm3jhrt2dav524 12 15 Tyrosine Tyrosine NNP work_ksthdbpq7vbwdm3jhrt2dav524 12 16 kinase kinase NN work_ksthdbpq7vbwdm3jhrt2dav524 12 17 inhibitors inhibitor NNS work_ksthdbpq7vbwdm3jhrt2dav524 12 18 . . . work_ksthdbpq7vbwdm3jhrt2dav524 13 1 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 13 2 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 13 3 Thorac Thorac NNP work_ksthdbpq7vbwdm3jhrt2dav524 13 4 Oncol Oncol NNP work_ksthdbpq7vbwdm3jhrt2dav524 13 5 . . . work_ksthdbpq7vbwdm3jhrt2dav524 14 1 2012;7 2012;7 LS work_ksthdbpq7vbwdm3jhrt2dav524 14 2 : : : work_ksthdbpq7vbwdm3jhrt2dav524 14 3 760–763 760–763 CD work_ksthdbpq7vbwdm3jhrt2dav524 14 4 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 14 5 Despite despite IN work_ksthdbpq7vbwdm3jhrt2dav524 14 6 advances advance NNS work_ksthdbpq7vbwdm3jhrt2dav524 14 7 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 14 8 staging staging NN work_ksthdbpq7vbwdm3jhrt2dav524 14 9 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 14 10 treatment treatment NN work_ksthdbpq7vbwdm3jhrt2dav524 14 11 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 14 12 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 14 13 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 14 14 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 14 15 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 14 16 , , , work_ksthdbpq7vbwdm3jhrt2dav524 14 17 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 14 18 relative relative JJ work_ksthdbpq7vbwdm3jhrt2dav524 14 19 5-year 5-year CD work_ksthdbpq7vbwdm3jhrt2dav524 14 20 survival survival NN work_ksthdbpq7vbwdm3jhrt2dav524 14 21 rate rate NN work_ksthdbpq7vbwdm3jhrt2dav524 14 22 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 14 23 all all DT work_ksthdbpq7vbwdm3jhrt2dav524 14 24 stages stage NNS work_ksthdbpq7vbwdm3jhrt2dav524 14 25 remained remain VBD work_ksthdbpq7vbwdm3jhrt2dav524 14 26 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 14 27 an an DT work_ksthdbpq7vbwdm3jhrt2dav524 14 28 estimated estimate VBN work_ksthdbpq7vbwdm3jhrt2dav524 14 29 19 19 CD work_ksthdbpq7vbwdm3jhrt2dav524 14 30 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 14 31 between between IN work_ksthdbpq7vbwdm3jhrt2dav524 14 32 1999 1999 CD work_ksthdbpq7vbwdm3jhrt2dav524 14 33 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 14 34 2005.1 2005.1 CD work_ksthdbpq7vbwdm3jhrt2dav524 14 35 Response Response NNP work_ksthdbpq7vbwdm3jhrt2dav524 14 36 rates rate NNS work_ksthdbpq7vbwdm3jhrt2dav524 14 37 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 14 38 RRs rr NNS work_ksthdbpq7vbwdm3jhrt2dav524 14 39 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 14 40 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 14 41 classic classic JJ work_ksthdbpq7vbwdm3jhrt2dav524 14 42 chemotherapeutic chemotherapeutic JJ work_ksthdbpq7vbwdm3jhrt2dav524 14 43 regimens regimen NNS work_ksthdbpq7vbwdm3jhrt2dav524 14 44 range range NN work_ksthdbpq7vbwdm3jhrt2dav524 14 45 from from IN work_ksthdbpq7vbwdm3jhrt2dav524 14 46 15 15 CD work_ksthdbpq7vbwdm3jhrt2dav524 14 47 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 14 48 48 48 CD work_ksthdbpq7vbwdm3jhrt2dav524 14 49 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 14 50 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 14 51 are be VBP work_ksthdbpq7vbwdm3jhrt2dav524 14 52 typically typically RB work_ksthdbpq7vbwdm3jhrt2dav524 14 53 short short JJ work_ksthdbpq7vbwdm3jhrt2dav524 14 54 in in RB work_ksthdbpq7vbwdm3jhrt2dav524 14 55 duration.2,3 duration.2,3 NNP work_ksthdbpq7vbwdm3jhrt2dav524 14 56 Angiogenesis Angiogenesis NNP work_ksthdbpq7vbwdm3jhrt2dav524 14 57 is be VBZ work_ksthdbpq7vbwdm3jhrt2dav524 14 58 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 14 59 critical critical JJ work_ksthdbpq7vbwdm3jhrt2dav524 14 60 factor factor NN work_ksthdbpq7vbwdm3jhrt2dav524 14 61 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 14 62 tumor tumor NN work_ksthdbpq7vbwdm3jhrt2dav524 14 63 growth growth NN work_ksthdbpq7vbwdm3jhrt2dav524 14 64 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 14 65 meta- meta- JJ work_ksthdbpq7vbwdm3jhrt2dav524 14 66 static static JJ work_ksthdbpq7vbwdm3jhrt2dav524 14 67 spread spread NN work_ksthdbpq7vbwdm3jhrt2dav524 14 68 . . . work_ksthdbpq7vbwdm3jhrt2dav524 15 1 In in IN work_ksthdbpq7vbwdm3jhrt2dav524 15 2 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 15 3 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 15 4 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 15 5 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 15 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 15 7 30 30 CD work_ksthdbpq7vbwdm3jhrt2dav524 15 8 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 15 9 60 60 CD work_ksthdbpq7vbwdm3jhrt2dav524 15 10 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 15 11 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 15 12 them -PRON- PRP work_ksthdbpq7vbwdm3jhrt2dav524 15 13 have have VBP work_ksthdbpq7vbwdm3jhrt2dav524 15 14 overexpression overexpression NN work_ksthdbpq7vbwdm3jhrt2dav524 15 15 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 15 16 vascular vascular JJ work_ksthdbpq7vbwdm3jhrt2dav524 15 17 endothelial endothelial JJ work_ksthdbpq7vbwdm3jhrt2dav524 15 18 growth growth NN work_ksthdbpq7vbwdm3jhrt2dav524 15 19 fac- fac- NN work_ksthdbpq7vbwdm3jhrt2dav524 15 20 tor tor NN work_ksthdbpq7vbwdm3jhrt2dav524 15 21 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 15 22 VEGF VEGF NNP work_ksthdbpq7vbwdm3jhrt2dav524 15 23 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 15 24 , , , work_ksthdbpq7vbwdm3jhrt2dav524 15 25 which which WDT work_ksthdbpq7vbwdm3jhrt2dav524 15 26 has have VBZ work_ksthdbpq7vbwdm3jhrt2dav524 15 27 been be VBN work_ksthdbpq7vbwdm3jhrt2dav524 15 28 correlated correlate VBN work_ksthdbpq7vbwdm3jhrt2dav524 15 29 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 15 30 greater great JJR work_ksthdbpq7vbwdm3jhrt2dav524 15 31 microves- microves- NNP work_ksthdbpq7vbwdm3jhrt2dav524 15 32 sel sel NNP work_ksthdbpq7vbwdm3jhrt2dav524 15 33 density density NN work_ksthdbpq7vbwdm3jhrt2dav524 15 34 , , , work_ksthdbpq7vbwdm3jhrt2dav524 15 35 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 15 36 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 15 37 , , , work_ksthdbpq7vbwdm3jhrt2dav524 15 38 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 15 39 poor poor JJ work_ksthdbpq7vbwdm3jhrt2dav524 15 40 prognosis.4 prognosis.4 NN work_ksthdbpq7vbwdm3jhrt2dav524 15 41 Inhibition inhibition NN work_ksthdbpq7vbwdm3jhrt2dav524 15 42 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 15 43 angiogenesis angiogenesis NN work_ksthdbpq7vbwdm3jhrt2dav524 15 44 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 15 45 compounds compound NNS work_ksthdbpq7vbwdm3jhrt2dav524 15 46 like like IN work_ksthdbpq7vbwdm3jhrt2dav524 15 47 sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 15 48 maleate maleate NN work_ksthdbpq7vbwdm3jhrt2dav524 15 49 , , , work_ksthdbpq7vbwdm3jhrt2dav524 15 50 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 15 51 well well RB work_ksthdbpq7vbwdm3jhrt2dav524 15 52 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 15 53 tolerated tolerate VBN work_ksthdbpq7vbwdm3jhrt2dav524 15 54 oral oral JJ work_ksthdbpq7vbwdm3jhrt2dav524 15 55 inhibitor inhibitor NN work_ksthdbpq7vbwdm3jhrt2dav524 15 56 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 15 57 tyrosine tyrosine JJ work_ksthdbpq7vbwdm3jhrt2dav524 15 58 kinase kinase NN work_ksthdbpq7vbwdm3jhrt2dav524 15 59 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 15 60 activity activity NN work_ksthdbpq7vbwdm3jhrt2dav524 15 61 against against IN work_ksthdbpq7vbwdm3jhrt2dav524 15 62 VEGF VEGF NNP work_ksthdbpq7vbwdm3jhrt2dav524 15 63 receptors receptor NNS work_ksthdbpq7vbwdm3jhrt2dav524 15 64 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 15 65 types type NNS work_ksthdbpq7vbwdm3jhrt2dav524 15 66 1–3 1–3 CD work_ksthdbpq7vbwdm3jhrt2dav524 15 67 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 15 68 , , , work_ksthdbpq7vbwdm3jhrt2dav524 15 69 platelet platelet NN work_ksthdbpq7vbwdm3jhrt2dav524 15 70 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 15 71 derived derive VBN work_ksthdbpq7vbwdm3jhrt2dav524 15 72 growth growth NN work_ksthdbpq7vbwdm3jhrt2dav524 15 73 factor factor NN work_ksthdbpq7vbwdm3jhrt2dav524 15 74 a a NN work_ksthdbpq7vbwdm3jhrt2dav524 15 75 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 15 76 platelet platelet RB work_ksthdbpq7vbwdm3jhrt2dav524 15 77 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 15 78 derived derive VBN work_ksthdbpq7vbwdm3jhrt2dav524 15 79 growth growth NN work_ksthdbpq7vbwdm3jhrt2dav524 15 80 factor factor NN work_ksthdbpq7vbwdm3jhrt2dav524 15 81   NNS work_ksthdbpq7vbwdm3jhrt2dav524 15 82 , , , work_ksthdbpq7vbwdm3jhrt2dav524 15 83 c c NN work_ksthdbpq7vbwdm3jhrt2dav524 15 84 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 15 85 kit kit NNP work_ksthdbpq7vbwdm3jhrt2dav524 15 86 , , , work_ksthdbpq7vbwdm3jhrt2dav524 15 87 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 15 88 fetal fetal JJ work_ksthdbpq7vbwdm3jhrt2dav524 15 89 liver liver NN work_ksthdbpq7vbwdm3jhrt2dav524 15 90 tyrosine tyrosine NN work_ksthdbpq7vbwdm3jhrt2dav524 15 91 kinase kinase NNP work_ksthdbpq7vbwdm3jhrt2dav524 15 92 receptor receptor NN work_ksthdbpq7vbwdm3jhrt2dav524 15 93 3,5 3,5 CD work_ksthdbpq7vbwdm3jhrt2dav524 15 94 is be VBZ work_ksthdbpq7vbwdm3jhrt2dav524 15 95 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 15 96 novel novel JJ work_ksthdbpq7vbwdm3jhrt2dav524 15 97 therapeutic therapeutic JJ work_ksthdbpq7vbwdm3jhrt2dav524 15 98 approach approach NN work_ksthdbpq7vbwdm3jhrt2dav524 15 99 that that WDT work_ksthdbpq7vbwdm3jhrt2dav524 15 100 has have VBZ work_ksthdbpq7vbwdm3jhrt2dav524 15 101 demonstrated demonstrate VBN work_ksthdbpq7vbwdm3jhrt2dav524 15 102 activity activity NN work_ksthdbpq7vbwdm3jhrt2dav524 15 103 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 15 104 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 15 105 variety variety NN work_ksthdbpq7vbwdm3jhrt2dav524 15 106 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 15 107 malig- malig- JJ work_ksthdbpq7vbwdm3jhrt2dav524 15 108 nancies nancy NNS work_ksthdbpq7vbwdm3jhrt2dav524 15 109 . . . work_ksthdbpq7vbwdm3jhrt2dav524 16 1 In in IN work_ksthdbpq7vbwdm3jhrt2dav524 16 2 preclinical preclinical JJ work_ksthdbpq7vbwdm3jhrt2dav524 16 3 studies study NNS work_ksthdbpq7vbwdm3jhrt2dav524 16 4 , , , work_ksthdbpq7vbwdm3jhrt2dav524 16 5 gastric gastric JJ work_ksthdbpq7vbwdm3jhrt2dav524 16 6 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 16 7 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 16 8 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 16 9 cell cell NN work_ksthdbpq7vbwdm3jhrt2dav524 16 10 lines line NNS work_ksthdbpq7vbwdm3jhrt2dav524 16 11 overexpressed overexpresse VBD work_ksthdbpq7vbwdm3jhrt2dav524 16 12 VEGF VEGF NNP work_ksthdbpq7vbwdm3jhrt2dav524 16 13 , , , work_ksthdbpq7vbwdm3jhrt2dav524 16 14 proliferated proliferate VBN work_ksthdbpq7vbwdm3jhrt2dav524 16 15 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 16 16 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 16 17 presence presence NN work_ksthdbpq7vbwdm3jhrt2dav524 16 18 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 16 19 recombinant recombinant JJ work_ksthdbpq7vbwdm3jhrt2dav524 16 20 VEGF vegf NN work_ksthdbpq7vbwdm3jhrt2dav524 16 21 , , , work_ksthdbpq7vbwdm3jhrt2dav524 16 22 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 16 23 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 16 24 inhibited inhibit VBN work_ksthdbpq7vbwdm3jhrt2dav524 16 25 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 16 26 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 16 27 dose dose RB work_ksthdbpq7vbwdm3jhrt2dav524 16 28 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 16 29 dependent dependent JJ work_ksthdbpq7vbwdm3jhrt2dav524 16 30 manner manner NN work_ksthdbpq7vbwdm3jhrt2dav524 16 31 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 16 32 sunitinib.6 sunitinib.6 CD work_ksthdbpq7vbwdm3jhrt2dav524 16 33 Sunitinib Sunitinib NNP work_ksthdbpq7vbwdm3jhrt2dav524 16 34 has have VBZ work_ksthdbpq7vbwdm3jhrt2dav524 16 35 been be VBN work_ksthdbpq7vbwdm3jhrt2dav524 16 36 studied study VBN work_ksthdbpq7vbwdm3jhrt2dav524 16 37 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 16 38 locally locally RB work_ksthdbpq7vbwdm3jhrt2dav524 16 39 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 16 40 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 16 41 cancer7 cancer7 NN work_ksthdbpq7vbwdm3jhrt2dav524 16 42 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 16 43 studies study NNS work_ksthdbpq7vbwdm3jhrt2dav524 16 44 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 16 45 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 16 46 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 16 47 relapsed relapsed JJ work_ksthdbpq7vbwdm3jhrt2dav524 16 48 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 16 49 refractory refractory JJ work_ksthdbpq7vbwdm3jhrt2dav524 16 50 metastatic metastatic JJ work_ksthdbpq7vbwdm3jhrt2dav524 16 51 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 16 52 are be VBP work_ksthdbpq7vbwdm3jhrt2dav524 16 53 ongoing ongoing JJ work_ksthdbpq7vbwdm3jhrt2dav524 16 54 . . . work_ksthdbpq7vbwdm3jhrt2dav524 17 1 on on IN work_ksthdbpq7vbwdm3jhrt2dav524 17 2 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 17 3 basis basis NN work_ksthdbpq7vbwdm3jhrt2dav524 17 4 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 17 5 this this DT work_ksthdbpq7vbwdm3jhrt2dav524 17 6 preclinical preclinical JJ work_ksthdbpq7vbwdm3jhrt2dav524 17 7 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 17 8 clinical clinical JJ work_ksthdbpq7vbwdm3jhrt2dav524 17 9 work work NN work_ksthdbpq7vbwdm3jhrt2dav524 17 10 , , , work_ksthdbpq7vbwdm3jhrt2dav524 17 11 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 17 12 known know VBN work_ksthdbpq7vbwdm3jhrt2dav524 17 13 overex- overex- JJ work_ksthdbpq7vbwdm3jhrt2dav524 17 14 pression pression NN work_ksthdbpq7vbwdm3jhrt2dav524 17 15 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 17 16 VEGF vegf NN work_ksthdbpq7vbwdm3jhrt2dav524 17 17 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 17 18 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 17 19 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 17 20 , , , work_ksthdbpq7vbwdm3jhrt2dav524 17 21 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 17 22 hypothesized hypothesize VBN work_ksthdbpq7vbwdm3jhrt2dav524 17 23 syn- syn- JJ work_ksthdbpq7vbwdm3jhrt2dav524 17 24 ergy ergy NN work_ksthdbpq7vbwdm3jhrt2dav524 17 25 between between IN work_ksthdbpq7vbwdm3jhrt2dav524 17 26 VEGF vegf NN work_ksthdbpq7vbwdm3jhrt2dav524 17 27 inhibition inhibition NN work_ksthdbpq7vbwdm3jhrt2dav524 17 28 , , , work_ksthdbpq7vbwdm3jhrt2dav524 17 29 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 17 30 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 17 31 antiangiogenic antiangiogenic JJ work_ksthdbpq7vbwdm3jhrt2dav524 17 32 effects effect NNS work_ksthdbpq7vbwdm3jhrt2dav524 17 33 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 17 34 taxane taxane NN work_ksthdbpq7vbwdm3jhrt2dav524 17 35 therapy,4 therapy,4 NNP work_ksthdbpq7vbwdm3jhrt2dav524 17 36 we -PRON- PRP work_ksthdbpq7vbwdm3jhrt2dav524 17 37 conducted conduct VBD work_ksthdbpq7vbwdm3jhrt2dav524 17 38 this this DT work_ksthdbpq7vbwdm3jhrt2dav524 17 39 multi multi JJ work_ksthdbpq7vbwdm3jhrt2dav524 17 40 - - JJ work_ksthdbpq7vbwdm3jhrt2dav524 17 41 institutional institutional JJ work_ksthdbpq7vbwdm3jhrt2dav524 17 42 phase phase NN work_ksthdbpq7vbwdm3jhrt2dav524 17 43 II ii CD work_ksthdbpq7vbwdm3jhrt2dav524 17 44 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 17 45 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 17 46 evaluate evaluate VB work_ksthdbpq7vbwdm3jhrt2dav524 17 47 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 17 48 efficacy efficacy NN work_ksthdbpq7vbwdm3jhrt2dav524 17 49 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 17 50 sunitinib sunitinib NNP work_ksthdbpq7vbwdm3jhrt2dav524 17 51 + + SYM work_ksthdbpq7vbwdm3jhrt2dav524 17 52 paclitaxel paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 17 53 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 17 54 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 17 55 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 17 56 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 17 57 esophageal esophageal NN work_ksthdbpq7vbwdm3jhrt2dav524 17 58 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 17 59 gastroesophageal gastroesophageal NN work_ksthdbpq7vbwdm3jhrt2dav524 17 60 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 17 61 GE GE NNP work_ksthdbpq7vbwdm3jhrt2dav524 17 62 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 17 63 junction junction NN work_ksthdbpq7vbwdm3jhrt2dav524 17 64 carcinoma carcinoma NN work_ksthdbpq7vbwdm3jhrt2dav524 17 65 . . . work_ksthdbpq7vbwdm3jhrt2dav524 18 1 PATIENTS patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 18 2 AND and CC work_ksthdbpq7vbwdm3jhrt2dav524 18 3 METHODS methods JJ work_ksthdbpq7vbwdm3jhrt2dav524 18 4 Patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 18 5 enrolled enrol VBD work_ksthdbpq7vbwdm3jhrt2dav524 18 6 on on IN work_ksthdbpq7vbwdm3jhrt2dav524 18 7 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 18 8 included include VBD work_ksthdbpq7vbwdm3jhrt2dav524 18 9 adults adult NNS work_ksthdbpq7vbwdm3jhrt2dav524 18 10 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 18 11 histo- histo- NN work_ksthdbpq7vbwdm3jhrt2dav524 18 12 logically logically RB work_ksthdbpq7vbwdm3jhrt2dav524 18 13 proven prove VBN work_ksthdbpq7vbwdm3jhrt2dav524 18 14 recurrent recurrent JJ work_ksthdbpq7vbwdm3jhrt2dav524 18 15 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 18 16 metastatic metastatic JJ work_ksthdbpq7vbwdm3jhrt2dav524 18 17 esophageal esophageal NN work_ksthdbpq7vbwdm3jhrt2dav524 18 18 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 18 19 GE GE NNP work_ksthdbpq7vbwdm3jhrt2dav524 18 20 junction junction NN work_ksthdbpq7vbwdm3jhrt2dav524 18 21 squamous squamous JJ work_ksthdbpq7vbwdm3jhrt2dav524 18 22 cell cell NN work_ksthdbpq7vbwdm3jhrt2dav524 18 23 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 18 24 adenocarcinoma adenocarcinoma NNP work_ksthdbpq7vbwdm3jhrt2dav524 18 25 , , , work_ksthdbpq7vbwdm3jhrt2dav524 18 26 who who WP work_ksthdbpq7vbwdm3jhrt2dav524 18 27 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 18 28 received receive VBN work_ksthdbpq7vbwdm3jhrt2dav524 18 29 less less JJR work_ksthdbpq7vbwdm3jhrt2dav524 18 30 than than IN work_ksthdbpq7vbwdm3jhrt2dav524 18 31 two two CD work_ksthdbpq7vbwdm3jhrt2dav524 18 32 chemotherapy chemotherapy NN work_ksthdbpq7vbwdm3jhrt2dav524 18 33 regimens regimen VBZ work_ksthdbpq7vbwdm3jhrt2dav524 18 34 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 18 35 locally locally RB work_ksthdbpq7vbwdm3jhrt2dav524 18 36 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 18 37 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 18 38 metastatic metastatic JJ work_ksthdbpq7vbwdm3jhrt2dav524 18 39 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 18 40 , , , work_ksthdbpq7vbwdm3jhrt2dav524 18 41 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 18 42 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 18 43 measurable measurable JJ work_ksthdbpq7vbwdm3jhrt2dav524 18 44 and/or and/or CC work_ksthdbpq7vbwdm3jhrt2dav524 18 45 evaluable evaluable JJ work_ksthdbpq7vbwdm3jhrt2dav524 18 46 dis- dis- NN work_ksthdbpq7vbwdm3jhrt2dav524 18 47 ease ease NN work_ksthdbpq7vbwdm3jhrt2dav524 18 48 as as IN work_ksthdbpq7vbwdm3jhrt2dav524 18 49 per per IN work_ksthdbpq7vbwdm3jhrt2dav524 18 50 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 18 51 Response Response NNP work_ksthdbpq7vbwdm3jhrt2dav524 18 52 Evaluation Evaluation NNP work_ksthdbpq7vbwdm3jhrt2dav524 18 53 Criteria Criteria NNP work_ksthdbpq7vbwdm3jhrt2dav524 18 54 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 18 55 Solid Solid NNP work_ksthdbpq7vbwdm3jhrt2dav524 18 56 Tumors Tumors NNP work_ksthdbpq7vbwdm3jhrt2dav524 18 57 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 18 58 RECIST RECIST NNP work_ksthdbpq7vbwdm3jhrt2dav524 18 59 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 18 60 criteria criterion NNS work_ksthdbpq7vbwdm3jhrt2dav524 18 61 . . . work_ksthdbpq7vbwdm3jhrt2dav524 19 1 All all DT work_ksthdbpq7vbwdm3jhrt2dav524 19 2 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 19 3 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 19 4 an an DT work_ksthdbpq7vbwdm3jhrt2dav524 19 5 Eastern Eastern NNP work_ksthdbpq7vbwdm3jhrt2dav524 19 6 Cooperative Cooperative NNP work_ksthdbpq7vbwdm3jhrt2dav524 19 7 oncology oncology NN work_ksthdbpq7vbwdm3jhrt2dav524 19 8 Group Group NNP work_ksthdbpq7vbwdm3jhrt2dav524 19 9 performance performance NN work_ksthdbpq7vbwdm3jhrt2dav524 19 10 status status NN work_ksthdbpq7vbwdm3jhrt2dav524 19 11 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 19 12 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 19 13 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 19 14 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 19 15 . . . work_ksthdbpq7vbwdm3jhrt2dav524 20 1 Key key JJ work_ksthdbpq7vbwdm3jhrt2dav524 20 2 exclusion exclusion NN work_ksthdbpq7vbwdm3jhrt2dav524 20 3 criteria criterion NNS work_ksthdbpq7vbwdm3jhrt2dav524 20 4 included include VBD work_ksthdbpq7vbwdm3jhrt2dav524 20 5 prior prior JJ work_ksthdbpq7vbwdm3jhrt2dav524 20 6 exposure exposure NN work_ksthdbpq7vbwdm3jhrt2dav524 20 7 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 20 8 an an DT work_ksthdbpq7vbwdm3jhrt2dav524 20 9 epidermal epidermal JJ work_ksthdbpq7vbwdm3jhrt2dav524 20 10 growth growth NN work_ksthdbpq7vbwdm3jhrt2dav524 20 11 factor factor NN work_ksthdbpq7vbwdm3jhrt2dav524 20 12 receptor receptor NN work_ksthdbpq7vbwdm3jhrt2dav524 20 13 inhibitor inhibitor NN work_ksthdbpq7vbwdm3jhrt2dav524 20 14 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 20 15 any any DT work_ksthdbpq7vbwdm3jhrt2dav524 20 16 other other JJ work_ksthdbpq7vbwdm3jhrt2dav524 20 17 antiangiogenic antiangiogenic JJ work_ksthdbpq7vbwdm3jhrt2dav524 20 18 agents agent NNS work_ksthdbpq7vbwdm3jhrt2dav524 20 19 . . . work_ksthdbpq7vbwdm3jhrt2dav524 21 1 Each each DT work_ksthdbpq7vbwdm3jhrt2dav524 21 2 treatment treatment NN work_ksthdbpq7vbwdm3jhrt2dav524 21 3 cycle cycle NN work_ksthdbpq7vbwdm3jhrt2dav524 21 4 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 21 5 defined define VBN work_ksthdbpq7vbwdm3jhrt2dav524 21 6 as as IN work_ksthdbpq7vbwdm3jhrt2dav524 21 7 28 28 CD work_ksthdbpq7vbwdm3jhrt2dav524 21 8 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 21 9 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 21 10 included include VBD work_ksthdbpq7vbwdm3jhrt2dav524 21 11 paclitaxel paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 12 90 90 CD work_ksthdbpq7vbwdm3jhrt2dav524 21 13 mg mg NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 14 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 21 15 m2 m2 NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 16 intravenous intravenous JJ work_ksthdbpq7vbwdm3jhrt2dav524 21 17 infusion infusion NN work_ksthdbpq7vbwdm3jhrt2dav524 21 18 over over IN work_ksthdbpq7vbwdm3jhrt2dav524 21 19 60 60 CD work_ksthdbpq7vbwdm3jhrt2dav524 21 20 minutes minute NNS work_ksthdbpq7vbwdm3jhrt2dav524 21 21 on on IN work_ksthdbpq7vbwdm3jhrt2dav524 21 22 * * NFP work_ksthdbpq7vbwdm3jhrt2dav524 21 23 Indiana Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 24 University University NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 25 Simon Simon NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 26 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 27 Center Center NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 28 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 29 Indianapolis Indianapolis NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 30 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 31 Indiana Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 32 ; ; : work_ksthdbpq7vbwdm3jhrt2dav524 21 33 †Indiana †Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 34 University University NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 35 Medical Medical NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 36 Center Center NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 37 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 38 Indianapolis Indianapolis NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 39 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 40 Indiana Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 41 ; ; : work_ksthdbpq7vbwdm3jhrt2dav524 21 42 ‡South ‡South NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 43 Carolina Carolina NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 44 oncology oncology NN work_ksthdbpq7vbwdm3jhrt2dav524 21 45 Associates Associates NNPS work_ksthdbpq7vbwdm3jhrt2dav524 21 46 PA PA NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 47 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 48 Columbia Columbia NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 49 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 50 South South NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 51 Carolina Carolina NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 52 ; ; : work_ksthdbpq7vbwdm3jhrt2dav524 21 53 § § ADD work_ksthdbpq7vbwdm3jhrt2dav524 21 54 Hoosier Hoosier NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 55 oncology oncology NN work_ksthdbpq7vbwdm3jhrt2dav524 21 56 Group Group NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 57 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 58     _SP work_ksthdbpq7vbwdm3jhrt2dav524 21 59 Indianapolis Indianapolis NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 60 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 61     _SP work_ksthdbpq7vbwdm3jhrt2dav524 21 62 Indiana Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 63 ; ; : work_ksthdbpq7vbwdm3jhrt2dav524 21 64     _SP work_ksthdbpq7vbwdm3jhrt2dav524 21 65 •Medical •Medical NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 66     _SP work_ksthdbpq7vbwdm3jhrt2dav524 21 67 Consultants Consultants NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 68 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 69     _SP work_ksthdbpq7vbwdm3jhrt2dav524 21 70 PC PC NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 71 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 72     _SP work_ksthdbpq7vbwdm3jhrt2dav524 21 73 Muncie Muncie NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 74 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 75     _SP work_ksthdbpq7vbwdm3jhrt2dav524 21 76 Indiana Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 77 ; ; : work_ksthdbpq7vbwdm3jhrt2dav524 21 78 ¶Northern ¶Northern NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 79 Indiana Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 80 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 81 Research Research NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 82 Consortium Consortium NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 83 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 84 South South NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 85 Bend Bend NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 86 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 87 Indiana Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 88 ; ; : work_ksthdbpq7vbwdm3jhrt2dav524 21 89 # # $ work_ksthdbpq7vbwdm3jhrt2dav524 21 90 Community Community NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 91 Hospital Hospital NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 92 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 93 Munster Munster NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 94 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 95 Indiana Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 96 ; ; : work_ksthdbpq7vbwdm3jhrt2dav524 21 97 * * NFP work_ksthdbpq7vbwdm3jhrt2dav524 21 98 * * NFP work_ksthdbpq7vbwdm3jhrt2dav524 21 99 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 100 Care Care NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 101 Center Center NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 102 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 21 103 Southern Southern NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 104 Indiana Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 105 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 106 Bloomington Bloomington NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 107 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 108 Indiana Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 109 ; ; : work_ksthdbpq7vbwdm3jhrt2dav524 21 110 ††Medical ††medical JJ work_ksthdbpq7vbwdm3jhrt2dav524 21 111 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 21 112 Surgical Surgical NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 113 Specialists Specialists NNPS work_ksthdbpq7vbwdm3jhrt2dav524 21 114 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 115 LLC LLC NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 116 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 117 Galesburg Galesburg NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 118 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 119 Illinois Illinois NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 120 ; ; : work_ksthdbpq7vbwdm3jhrt2dav524 21 121 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 21 122 ‡‡Indiana ‡‡Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 123 University University NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 124 Division Division NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 125 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 21 126 Biostatistics Biostatistics NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 127 Indianapolis Indianapolis NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 128 , , , work_ksthdbpq7vbwdm3jhrt2dav524 21 129 Indiana Indiana NNP work_ksthdbpq7vbwdm3jhrt2dav524 21 130 . . . work_ksthdbpq7vbwdm3jhrt2dav524 22 1 Disclosure disclosure NN work_ksthdbpq7vbwdm3jhrt2dav524 22 2 : : : work_ksthdbpq7vbwdm3jhrt2dav524 22 3 This this DT work_ksthdbpq7vbwdm3jhrt2dav524 22 4 work work NN work_ksthdbpq7vbwdm3jhrt2dav524 22 5 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 22 6 supported support VBN work_ksthdbpq7vbwdm3jhrt2dav524 22 7 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 22 8 Pfizer Pfizer NNP work_ksthdbpq7vbwdm3jhrt2dav524 22 9 . . . work_ksthdbpq7vbwdm3jhrt2dav524 23 1 Address address NN work_ksthdbpq7vbwdm3jhrt2dav524 23 2 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 23 3 correspondence correspondence NN work_ksthdbpq7vbwdm3jhrt2dav524 23 4 : : : work_ksthdbpq7vbwdm3jhrt2dav524 23 5 Jordan Jordan NNP work_ksthdbpq7vbwdm3jhrt2dav524 23 6 Schmitt Schmitt NNP work_ksthdbpq7vbwdm3jhrt2dav524 23 7 , , , work_ksthdbpq7vbwdm3jhrt2dav524 23 8 MD MD NNP work_ksthdbpq7vbwdm3jhrt2dav524 23 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 23 10 535 535 CD work_ksthdbpq7vbwdm3jhrt2dav524 23 11 Barnhill Barnhill NNP work_ksthdbpq7vbwdm3jhrt2dav524 23 12 Drive Drive NNP work_ksthdbpq7vbwdm3jhrt2dav524 23 13 , , , work_ksthdbpq7vbwdm3jhrt2dav524 23 14 RT RT NNP work_ksthdbpq7vbwdm3jhrt2dav524 23 15 473 473 CD work_ksthdbpq7vbwdm3jhrt2dav524 23 16 , , , work_ksthdbpq7vbwdm3jhrt2dav524 23 17 Indianapolis Indianapolis NNP work_ksthdbpq7vbwdm3jhrt2dav524 23 18 , , , work_ksthdbpq7vbwdm3jhrt2dav524 23 19 IN in IN work_ksthdbpq7vbwdm3jhrt2dav524 23 20 46202 46202 CD work_ksthdbpq7vbwdm3jhrt2dav524 23 21 . . . work_ksthdbpq7vbwdm3jhrt2dav524 24 1 E e NN work_ksthdbpq7vbwdm3jhrt2dav524 24 2 - - NN work_ksthdbpq7vbwdm3jhrt2dav524 24 3 mail mail NN work_ksthdbpq7vbwdm3jhrt2dav524 24 4 : : : work_ksthdbpq7vbwdm3jhrt2dav524 24 5 jmw8@iupui.edu jmw8@iupui.edu NNS work_ksthdbpq7vbwdm3jhrt2dav524 24 6 Copyright copyright NN work_ksthdbpq7vbwdm3jhrt2dav524 24 7 © © NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 8 2012 2012 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 9 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 24 10 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 24 11 International International NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 12 Association Association NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 13 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 24 14 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 24 15 Study Study NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 16 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 24 17 Lung Lung NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 18 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 19 ISSN ISSN NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 20 : : : work_ksthdbpq7vbwdm3jhrt2dav524 24 21 1556 1556 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 22 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 24 23 0864/12/0704 0864/12/0704 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 24 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 24 25 0760 0760 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 26 Sunitinib Sunitinib NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 27 Plus Plus NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 28 Paclitaxel Paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 29 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 24 30 Patients Patients NNPS work_ksthdbpq7vbwdm3jhrt2dav524 24 31 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 24 32 Advanced Advanced NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 33 Esophageal esophageal NN work_ksthdbpq7vbwdm3jhrt2dav524 24 34 Cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 24 35 A A NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 36 Phase Phase NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 37 II II NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 38 Study study NN work_ksthdbpq7vbwdm3jhrt2dav524 24 39 from from IN work_ksthdbpq7vbwdm3jhrt2dav524 24 40 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 24 41 Hoosier Hoosier NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 42 Oncology Oncology NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 43 Group Group NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 44 Jordan Jordan NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 45 M. M. NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 46 Schmitt Schmitt NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 47 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 48 MD,*† MD,*† NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 49 Scott Scott NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 50 R. R. NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 51 Sommers Sommers NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 52 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 53 MD,‡ MD,‡ NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 54 William William NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 55 Fisher Fisher NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 56 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 57 MD,§• MD,§• NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 58 Rafat Rafat NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 59 Ansari Ansari NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 60 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 61 MD,§¶ md,§¶ RB work_ksthdbpq7vbwdm3jhrt2dav524 24 62 Erwin Erwin NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 63 Robin Robin NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 64 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 65 MD,§ MD,§ NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 66 # # NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 67 Karuna Karuna NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 68 Koneru Koneru NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 69 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 70 MD,§ MD,§ NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 71 * * NFP work_ksthdbpq7vbwdm3jhrt2dav524 24 72 * * NFP work_ksthdbpq7vbwdm3jhrt2dav524 24 73 John John NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 74 McClean McClean NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 75 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 76 MD,§†† MD,§†† NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 77 Ziyue Ziyue NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 78 Liu Liu NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 79 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 80 PhD,‡‡ PhD,‡‡ NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 81 Yan Yan NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 82 Tong Tong NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 83 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 84 MS,‡‡ MS,‡‡ NNS work_ksthdbpq7vbwdm3jhrt2dav524 24 85 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 24 86 Nasser Nasser NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 87 Hanna Hanna NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 88 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 89 MD*†§ MD*†§ NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 90 761Copyright 761copyright CD work_ksthdbpq7vbwdm3jhrt2dav524 24 91 © © CD work_ksthdbpq7vbwdm3jhrt2dav524 24 92 2012 2012 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 93 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 24 94 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 24 95 International International NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 96 Association Association NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 97 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 24 98 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 24 99 Study Study NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 100 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 24 101 Lung Lung NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 102 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 103 Journal Journal NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 104 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 24 105 Thoracic Thoracic NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 106 Oncology Oncology NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 107 • • NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 108 Volume volume NN work_ksthdbpq7vbwdm3jhrt2dav524 24 109 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 110 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 111 Number number NN work_ksthdbpq7vbwdm3jhrt2dav524 24 112 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 113 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 114 April April NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 115 2012 2012 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 116 Sunitinib Sunitinib NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 117 Plus Plus NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 118 Paclitaxel Paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 119 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 24 120 Esophageal Esophageal NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 121 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 122 Patients Patients NNPS work_ksthdbpq7vbwdm3jhrt2dav524 24 123 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 24 124 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 125 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 126 8 8 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 127 , , , work_ksthdbpq7vbwdm3jhrt2dav524 24 128 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 24 129 15 15 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 130 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 24 131 sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 24 132 maleate maleate NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 133 37.5 37.5 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 134 mg mg NNP work_ksthdbpq7vbwdm3jhrt2dav524 24 135 orally orally RB work_ksthdbpq7vbwdm3jhrt2dav524 24 136 daily.8 daily.8 CD work_ksthdbpq7vbwdm3jhrt2dav524 24 137 Participants participant NNS work_ksthdbpq7vbwdm3jhrt2dav524 24 138 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 24 139 scheduled schedule VBN work_ksthdbpq7vbwdm3jhrt2dav524 24 140 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 24 141 receive receive VB work_ksthdbpq7vbwdm3jhrt2dav524 24 142 four four CD work_ksthdbpq7vbwdm3jhrt2dav524 24 143 cycles cycle NNS work_ksthdbpq7vbwdm3jhrt2dav524 24 144 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 24 145 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 24 146 com- com- NN work_ksthdbpq7vbwdm3jhrt2dav524 24 147 bination bination NN work_ksthdbpq7vbwdm3jhrt2dav524 24 148 therapy therapy NN work_ksthdbpq7vbwdm3jhrt2dav524 24 149 . . . work_ksthdbpq7vbwdm3jhrt2dav524 25 1 Treatment treatment NN work_ksthdbpq7vbwdm3jhrt2dav524 25 2 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 25 3 discontinued discontinue VBN work_ksthdbpq7vbwdm3jhrt2dav524 25 4 upon upon IN work_ksthdbpq7vbwdm3jhrt2dav524 25 5 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 25 6 progression progression NN work_ksthdbpq7vbwdm3jhrt2dav524 25 7 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 25 8 unacceptable unacceptable JJ work_ksthdbpq7vbwdm3jhrt2dav524 25 9 toxicity toxicity NN work_ksthdbpq7vbwdm3jhrt2dav524 25 10 . . . work_ksthdbpq7vbwdm3jhrt2dav524 26 1 After after IN work_ksthdbpq7vbwdm3jhrt2dav524 26 2 four four CD work_ksthdbpq7vbwdm3jhrt2dav524 26 3 cycles cycle NNS work_ksthdbpq7vbwdm3jhrt2dav524 26 4 , , , work_ksthdbpq7vbwdm3jhrt2dav524 26 5 pacli- pacli- NNP work_ksthdbpq7vbwdm3jhrt2dav524 26 6 taxel taxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 26 7 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 26 8 discontinued discontinue VBN work_ksthdbpq7vbwdm3jhrt2dav524 26 9 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 26 10 each each DT work_ksthdbpq7vbwdm3jhrt2dav524 26 11 patient patient NN work_ksthdbpq7vbwdm3jhrt2dav524 26 12 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 26 13 allowed allow VBN work_ksthdbpq7vbwdm3jhrt2dav524 26 14 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 26 15 con- con- NNP work_ksthdbpq7vbwdm3jhrt2dav524 26 16 tinue tinue VB work_ksthdbpq7vbwdm3jhrt2dav524 26 17 on on IN work_ksthdbpq7vbwdm3jhrt2dav524 26 18 sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 26 19 maleate maleate NN work_ksthdbpq7vbwdm3jhrt2dav524 26 20 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 26 21 two two CD work_ksthdbpq7vbwdm3jhrt2dav524 26 22 more more JJR work_ksthdbpq7vbwdm3jhrt2dav524 26 23 cycles cycle NNS work_ksthdbpq7vbwdm3jhrt2dav524 26 24 provided provide VBN work_ksthdbpq7vbwdm3jhrt2dav524 26 25 he/ he/ UH work_ksthdbpq7vbwdm3jhrt2dav524 26 26 she -PRON- PRP work_ksthdbpq7vbwdm3jhrt2dav524 26 27 did do VBD work_ksthdbpq7vbwdm3jhrt2dav524 26 28 not not RB work_ksthdbpq7vbwdm3jhrt2dav524 26 29 have have VB work_ksthdbpq7vbwdm3jhrt2dav524 26 30 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 26 31 progression progression NN work_ksthdbpq7vbwdm3jhrt2dav524 26 32 , , , work_ksthdbpq7vbwdm3jhrt2dav524 26 33 intolerable intolerable JJ work_ksthdbpq7vbwdm3jhrt2dav524 26 34 side side NN work_ksthdbpq7vbwdm3jhrt2dav524 26 35 effects effect NNS work_ksthdbpq7vbwdm3jhrt2dav524 26 36 , , , work_ksthdbpq7vbwdm3jhrt2dav524 26 37 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 26 38 adverse adverse JJ work_ksthdbpq7vbwdm3jhrt2dav524 26 39 reactions reaction NNS work_ksthdbpq7vbwdm3jhrt2dav524 26 40 . . . work_ksthdbpq7vbwdm3jhrt2dav524 27 1 Patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 27 2 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 27 3 evaluated evaluate VBN work_ksthdbpq7vbwdm3jhrt2dav524 27 4 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 27 5 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 27 6 beginning beginning NN work_ksthdbpq7vbwdm3jhrt2dav524 27 7 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 27 8 each each DT work_ksthdbpq7vbwdm3jhrt2dav524 27 9 treat- treat- JJ work_ksthdbpq7vbwdm3jhrt2dav524 27 10 ment ment JJ work_ksthdbpq7vbwdm3jhrt2dav524 27 11 cycle cycle NN work_ksthdbpq7vbwdm3jhrt2dav524 27 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 28 1 Before before IN work_ksthdbpq7vbwdm3jhrt2dav524 28 2 odd odd JJ work_ksthdbpq7vbwdm3jhrt2dav524 28 3 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 28 4 numbered number VBN work_ksthdbpq7vbwdm3jhrt2dav524 28 5 cycles cycle NNS work_ksthdbpq7vbwdm3jhrt2dav524 28 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 28 7 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 28 8 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 28 9 evalu- evalu- VBZ work_ksthdbpq7vbwdm3jhrt2dav524 28 10 ation ation NN work_ksthdbpq7vbwdm3jhrt2dav524 28 11 per per IN work_ksthdbpq7vbwdm3jhrt2dav524 28 12 RECIST RECIST NNP work_ksthdbpq7vbwdm3jhrt2dav524 28 13 criteria criterion NNS work_ksthdbpq7vbwdm3jhrt2dav524 28 14 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 28 15 performed perform VBN work_ksthdbpq7vbwdm3jhrt2dav524 28 16 . . . work_ksthdbpq7vbwdm3jhrt2dav524 29 1 At at IN work_ksthdbpq7vbwdm3jhrt2dav524 29 2 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 29 3 end end NN work_ksthdbpq7vbwdm3jhrt2dav524 29 4 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 29 5 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 29 6 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 29 7 , , , work_ksthdbpq7vbwdm3jhrt2dav524 29 8 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 29 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 29 10 including include VBG work_ksthdbpq7vbwdm3jhrt2dav524 29 11 those those DT work_ksthdbpq7vbwdm3jhrt2dav524 29 12 who who WP work_ksthdbpq7vbwdm3jhrt2dav524 29 13 discontinued discontinue VBD work_ksthdbpq7vbwdm3jhrt2dav524 29 14 pro- pro- NN work_ksthdbpq7vbwdm3jhrt2dav524 29 15 tocol tocol NNP work_ksthdbpq7vbwdm3jhrt2dav524 29 16 therapy therapy NNP work_ksthdbpq7vbwdm3jhrt2dav524 29 17 early early RB work_ksthdbpq7vbwdm3jhrt2dav524 29 18 , , , work_ksthdbpq7vbwdm3jhrt2dav524 29 19 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 29 20 evaluated evaluate VBN work_ksthdbpq7vbwdm3jhrt2dav524 29 21 30 30 CD work_ksthdbpq7vbwdm3jhrt2dav524 29 22 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 29 23 after after IN work_ksthdbpq7vbwdm3jhrt2dav524 29 24 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 29 25 last last JJ work_ksthdbpq7vbwdm3jhrt2dav524 29 26 dose dose NN work_ksthdbpq7vbwdm3jhrt2dav524 29 27 . . . work_ksthdbpq7vbwdm3jhrt2dav524 30 1 Patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 30 2 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 30 3 then then RB work_ksthdbpq7vbwdm3jhrt2dav524 30 4 serially serially RB work_ksthdbpq7vbwdm3jhrt2dav524 30 5 followed follow VBN work_ksthdbpq7vbwdm3jhrt2dav524 30 6 up up RP work_ksthdbpq7vbwdm3jhrt2dav524 30 7 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 30 8 duration duration NN work_ksthdbpq7vbwdm3jhrt2dav524 30 9 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 30 10 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 30 11 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 30 12 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 30 13 survival survival NN work_ksthdbpq7vbwdm3jhrt2dav524 30 14 . . . work_ksthdbpq7vbwdm3jhrt2dav524 31 1 All all DT work_ksthdbpq7vbwdm3jhrt2dav524 31 2 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 31 3 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 31 4 measured measure VBN work_ksthdbpq7vbwdm3jhrt2dav524 31 5 according accord VBG work_ksthdbpq7vbwdm3jhrt2dav524 31 6 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 31 7 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 31 8 National National NNP work_ksthdbpq7vbwdm3jhrt2dav524 31 9 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 31 10 Institute Institute NNP work_ksthdbpq7vbwdm3jhrt2dav524 31 11 Common Common NNP work_ksthdbpq7vbwdm3jhrt2dav524 31 12 Toxicity Toxicity NNP work_ksthdbpq7vbwdm3jhrt2dav524 31 13 Criteria Criteria NNP work_ksthdbpq7vbwdm3jhrt2dav524 31 14 version version NN work_ksthdbpq7vbwdm3jhrt2dav524 31 15 3.0 3.0 CD work_ksthdbpq7vbwdm3jhrt2dav524 31 16 . . . work_ksthdbpq7vbwdm3jhrt2dav524 32 1 The the DT work_ksthdbpq7vbwdm3jhrt2dav524 32 2 primary primary JJ work_ksthdbpq7vbwdm3jhrt2dav524 32 3 end end NN work_ksthdbpq7vbwdm3jhrt2dav524 32 4 point point NN work_ksthdbpq7vbwdm3jhrt2dav524 32 5 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 32 6 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 32 7 rate rate NN work_ksthdbpq7vbwdm3jhrt2dav524 32 8 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 32 9 nonprogressive nonprogressive JJ work_ksthdbpq7vbwdm3jhrt2dav524 32 10 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 32 11 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 32 12 6 6 CD work_ksthdbpq7vbwdm3jhrt2dav524 32 13 months month NNS work_ksthdbpq7vbwdm3jhrt2dav524 32 14 . . . work_ksthdbpq7vbwdm3jhrt2dav524 33 1 Nonprogressive nonprogressive JJ work_ksthdbpq7vbwdm3jhrt2dav524 33 2 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 33 3 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 33 4 defined define VBN work_ksthdbpq7vbwdm3jhrt2dav524 33 5 as as IN work_ksthdbpq7vbwdm3jhrt2dav524 33 6 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 33 7 complete complete JJ work_ksthdbpq7vbwdm3jhrt2dav524 33 8 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 33 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 33 10 partial partial JJ work_ksthdbpq7vbwdm3jhrt2dav524 33 11 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 33 12 , , , work_ksthdbpq7vbwdm3jhrt2dav524 33 13 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 33 14 stable stable JJ work_ksthdbpq7vbwdm3jhrt2dav524 33 15 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 33 16 . . . work_ksthdbpq7vbwdm3jhrt2dav524 34 1 A a DT work_ksthdbpq7vbwdm3jhrt2dav524 34 2 pre- pre- RB work_ksthdbpq7vbwdm3jhrt2dav524 34 3 determined determine VBN work_ksthdbpq7vbwdm3jhrt2dav524 34 4 improvement improvement NN work_ksthdbpq7vbwdm3jhrt2dav524 34 5 from from IN work_ksthdbpq7vbwdm3jhrt2dav524 34 6 25 25 CD work_ksthdbpq7vbwdm3jhrt2dav524 34 7 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 34 8 50 50 CD work_ksthdbpq7vbwdm3jhrt2dav524 34 9 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 34 10 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 34 11 nonprogressive nonprogressive JJ work_ksthdbpq7vbwdm3jhrt2dav524 34 12 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 34 13 rate rate NN work_ksthdbpq7vbwdm3jhrt2dav524 34 14 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 34 15 deemed deem VBN work_ksthdbpq7vbwdm3jhrt2dav524 34 16 reasonable reasonable JJ work_ksthdbpq7vbwdm3jhrt2dav524 34 17 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 34 18 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 34 19 proposed propose VBN work_ksthdbpq7vbwdm3jhrt2dav524 34 20 regimen regimen NN work_ksthdbpq7vbwdm3jhrt2dav524 34 21 as as IN work_ksthdbpq7vbwdm3jhrt2dav524 34 22 two two CD work_ksthdbpq7vbwdm3jhrt2dav524 34 23 prior prior JJ work_ksthdbpq7vbwdm3jhrt2dav524 34 24 phase phase NN work_ksthdbpq7vbwdm3jhrt2dav524 34 25 II ii CD work_ksthdbpq7vbwdm3jhrt2dav524 34 26 trials trial NNS work_ksthdbpq7vbwdm3jhrt2dav524 34 27 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 34 28 paclitaxel paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 34 29 therapy therapy NN work_ksthdbpq7vbwdm3jhrt2dav524 34 30 alone alone RB work_ksthdbpq7vbwdm3jhrt2dav524 34 31 dem- dem- RB work_ksthdbpq7vbwdm3jhrt2dav524 34 32 onstrated onstrate VBD work_ksthdbpq7vbwdm3jhrt2dav524 34 33 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 34 34 median median JJ work_ksthdbpq7vbwdm3jhrt2dav524 34 35 duration duration NN work_ksthdbpq7vbwdm3jhrt2dav524 34 36 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 34 37 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 34 38 ranging range VBG work_ksthdbpq7vbwdm3jhrt2dav524 34 39 from from IN work_ksthdbpq7vbwdm3jhrt2dav524 34 40 119 119 CD work_ksthdbpq7vbwdm3jhrt2dav524 34 41 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 34 42 172 172 CD work_ksthdbpq7vbwdm3jhrt2dav524 34 43 days9,10 days9,10 NN work_ksthdbpq7vbwdm3jhrt2dav524 34 44 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 34 45 we -PRON- PRP work_ksthdbpq7vbwdm3jhrt2dav524 34 46 anticipated anticipate VBD work_ksthdbpq7vbwdm3jhrt2dav524 34 47 prolonged prolonged JJ work_ksthdbpq7vbwdm3jhrt2dav524 34 48 duration duration NN work_ksthdbpq7vbwdm3jhrt2dav524 34 49 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 34 50 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 34 51 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 34 52 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 34 53 addition addition NN work_ksthdbpq7vbwdm3jhrt2dav524 34 54 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 34 55 antiangiogenic antiangiogenic JJ work_ksthdbpq7vbwdm3jhrt2dav524 34 56 therapy therapy NN work_ksthdbpq7vbwdm3jhrt2dav524 34 57 . . . work_ksthdbpq7vbwdm3jhrt2dav524 35 1 With with IN work_ksthdbpq7vbwdm3jhrt2dav524 35 2 26 26 CD work_ksthdbpq7vbwdm3jhrt2dav524 35 3 subjects subject NNS work_ksthdbpq7vbwdm3jhrt2dav524 35 4 , , , work_ksthdbpq7vbwdm3jhrt2dav524 35 5 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 35 6 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 35 7 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 35 8 more more JJR work_ksthdbpq7vbwdm3jhrt2dav524 35 9 than than IN work_ksthdbpq7vbwdm3jhrt2dav524 35 10 80 80 CD work_ksthdbpq7vbwdm3jhrt2dav524 35 11 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 35 12 power power NN work_ksthdbpq7vbwdm3jhrt2dav524 35 13 based base VBN work_ksthdbpq7vbwdm3jhrt2dav524 35 14 on on IN work_ksthdbpq7vbwdm3jhrt2dav524 35 15 one one CD work_ksthdbpq7vbwdm3jhrt2dav524 35 16 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 35 17 sided sided JJ work_ksthdbpq7vbwdm3jhrt2dav524 35 18 test test NN work_ksthdbpq7vbwdm3jhrt2dav524 35 19 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 35 20 error error NN work_ksthdbpq7vbwdm3jhrt2dav524 35 21 rate rate NN work_ksthdbpq7vbwdm3jhrt2dav524 35 22 controlled control VBN work_ksthdbpq7vbwdm3jhrt2dav524 35 23 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 35 24 5 5 CD work_ksthdbpq7vbwdm3jhrt2dav524 35 25 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 35 26 . . . work_ksthdbpq7vbwdm3jhrt2dav524 36 1 RESULTS RESULTS NNP work_ksthdbpq7vbwdm3jhrt2dav524 36 2 Twenty twenty CD work_ksthdbpq7vbwdm3jhrt2dav524 36 3 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 36 4 eight eight CD work_ksthdbpq7vbwdm3jhrt2dav524 36 5 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 36 6 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 36 7 enrolled enrol VBN work_ksthdbpq7vbwdm3jhrt2dav524 36 8 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 36 9 six six CD work_ksthdbpq7vbwdm3jhrt2dav524 36 10 participating participate VBG work_ksthdbpq7vbwdm3jhrt2dav524 36 11 centers center NNS work_ksthdbpq7vbwdm3jhrt2dav524 36 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 37 1 Patient patient JJ work_ksthdbpq7vbwdm3jhrt2dav524 37 2 demographics demographic NNS work_ksthdbpq7vbwdm3jhrt2dav524 37 3 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 37 4 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 37 5 characteristics characteristic NNS work_ksthdbpq7vbwdm3jhrt2dav524 37 6 are be VBP work_ksthdbpq7vbwdm3jhrt2dav524 37 7 summarized summarize VBN work_ksthdbpq7vbwdm3jhrt2dav524 37 8 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 37 9 Table table NN work_ksthdbpq7vbwdm3jhrt2dav524 37 10 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 37 11 . . . work_ksthdbpq7vbwdm3jhrt2dav524 37 12 over over IN work_ksthdbpq7vbwdm3jhrt2dav524 37 13 80 80 CD work_ksthdbpq7vbwdm3jhrt2dav524 37 14 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 37 15 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 37 16 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 37 17 participants participant NNS work_ksthdbpq7vbwdm3jhrt2dav524 37 18 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 37 19 men man NNS work_ksthdbpq7vbwdm3jhrt2dav524 37 20 , , , work_ksthdbpq7vbwdm3jhrt2dav524 37 21 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 37 22 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 37 23 median median JJ work_ksthdbpq7vbwdm3jhrt2dav524 37 24 age age NN work_ksthdbpq7vbwdm3jhrt2dav524 37 25 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 37 26 enrollment enrollment NN work_ksthdbpq7vbwdm3jhrt2dav524 37 27 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 37 28 59.5 59.5 CD work_ksthdbpq7vbwdm3jhrt2dav524 37 29 years year NNS work_ksthdbpq7vbwdm3jhrt2dav524 37 30 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 37 31 age age NN work_ksthdbpq7vbwdm3jhrt2dav524 37 32 range range NN work_ksthdbpq7vbwdm3jhrt2dav524 37 33 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 37 34 40–84 40–84 CD work_ksthdbpq7vbwdm3jhrt2dav524 37 35 years year NNS work_ksthdbpq7vbwdm3jhrt2dav524 37 36 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 37 37 . . . work_ksthdbpq7vbwdm3jhrt2dav524 38 1 All all DT work_ksthdbpq7vbwdm3jhrt2dav524 38 2 tumors tumor NNS work_ksthdbpq7vbwdm3jhrt2dav524 38 3 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 38 4 located locate VBN work_ksthdbpq7vbwdm3jhrt2dav524 38 5 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 38 6 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 38 7 esophagus esophagus NN work_ksthdbpq7vbwdm3jhrt2dav524 38 8 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 38 9 22/28 22/28 CD work_ksthdbpq7vbwdm3jhrt2dav524 38 10 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 38 11 GE GE NNP work_ksthdbpq7vbwdm3jhrt2dav524 38 12 junction junction NN work_ksthdbpq7vbwdm3jhrt2dav524 38 13 [ [ -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 38 14 6/28 6/28 CD work_ksthdbpq7vbwdm3jhrt2dav524 38 15 ] ] -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 38 16 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 38 17 . . . work_ksthdbpq7vbwdm3jhrt2dav524 39 1 Ninety ninety CD work_ksthdbpq7vbwdm3jhrt2dav524 39 2 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 39 3 three three CD work_ksthdbpq7vbwdm3jhrt2dav524 39 4 percent percent NN work_ksthdbpq7vbwdm3jhrt2dav524 39 5 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 39 6 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 39 7 tumors tumor NNS work_ksthdbpq7vbwdm3jhrt2dav524 39 8 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 39 9 n n NNP work_ksthdbpq7vbwdm3jhrt2dav524 39 10 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 39 11 26 26 CD work_ksthdbpq7vbwdm3jhrt2dav524 39 12 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 39 13 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 39 14 adenocarcinoma adenocarcinoma NNP work_ksthdbpq7vbwdm3jhrt2dav524 39 15 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 39 16 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 39 17 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 39 18 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 39 19 n n NN work_ksthdbpq7vbwdm3jhrt2dav524 39 20 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 39 21 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 39 22 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 39 23 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 39 24 squamous squamous JJ work_ksthdbpq7vbwdm3jhrt2dav524 39 25 cell cell NN work_ksthdbpq7vbwdm3jhrt2dav524 39 26 carcinoma carcinoma NN work_ksthdbpq7vbwdm3jhrt2dav524 39 27 . . . work_ksthdbpq7vbwdm3jhrt2dav524 40 1 Nine nine CD work_ksthdbpq7vbwdm3jhrt2dav524 40 2 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 40 3 28 28 CD work_ksthdbpq7vbwdm3jhrt2dav524 40 4 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 40 5 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 40 6 received receive VBN work_ksthdbpq7vbwdm3jhrt2dav524 40 7 prior prior JJ work_ksthdbpq7vbwdm3jhrt2dav524 40 8 chemotherapy chemotherapy NN work_ksthdbpq7vbwdm3jhrt2dav524 40 9 . . . work_ksthdbpq7vbwdm3jhrt2dav524 41 1 The the DT work_ksthdbpq7vbwdm3jhrt2dav524 41 2 median median JJ work_ksthdbpq7vbwdm3jhrt2dav524 41 3 follow follow NN work_ksthdbpq7vbwdm3jhrt2dav524 41 4 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 41 5 up up NN work_ksthdbpq7vbwdm3jhrt2dav524 41 6 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 41 7 222 222 CD work_ksthdbpq7vbwdm3jhrt2dav524 41 8 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 41 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 41 10 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 41 11 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 41 12 range range NN work_ksthdbpq7vbwdm3jhrt2dav524 41 13 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 41 14 15 15 CD work_ksthdbpq7vbwdm3jhrt2dav524 41 15 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 41 16 629 629 CD work_ksthdbpq7vbwdm3jhrt2dav524 41 17 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 41 18 . . . work_ksthdbpq7vbwdm3jhrt2dav524 42 1 Six six CD work_ksthdbpq7vbwdm3jhrt2dav524 42 2 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 42 3 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 42 4 22 22 CD work_ksthdbpq7vbwdm3jhrt2dav524 42 5 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 42 6 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 42 7 completed complete VBD work_ksthdbpq7vbwdm3jhrt2dav524 42 8 less less JJR work_ksthdbpq7vbwdm3jhrt2dav524 42 9 than than IN work_ksthdbpq7vbwdm3jhrt2dav524 42 10 one one CD work_ksthdbpq7vbwdm3jhrt2dav524 42 11 cycle cycle NN work_ksthdbpq7vbwdm3jhrt2dav524 42 12 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 42 13 therapy therapy NN work_ksthdbpq7vbwdm3jhrt2dav524 42 14 . . . work_ksthdbpq7vbwdm3jhrt2dav524 43 1 Seven seven CD work_ksthdbpq7vbwdm3jhrt2dav524 43 2 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 43 3 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 43 4 25 25 CD work_ksthdbpq7vbwdm3jhrt2dav524 43 5 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 43 6 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 43 7 finished finish VBD work_ksthdbpq7vbwdm3jhrt2dav524 43 8 all all DT work_ksthdbpq7vbwdm3jhrt2dav524 43 9 four four CD work_ksthdbpq7vbwdm3jhrt2dav524 43 10 cycles cycle NNS work_ksthdbpq7vbwdm3jhrt2dav524 43 11 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 43 12 went go VBD work_ksthdbpq7vbwdm3jhrt2dav524 43 13 on on RP work_ksthdbpq7vbwdm3jhrt2dav524 43 14 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 43 15 receive receive VB work_ksthdbpq7vbwdm3jhrt2dav524 43 16 maintenance maintenance NN work_ksthdbpq7vbwdm3jhrt2dav524 43 17 treatment treatment NN work_ksthdbpq7vbwdm3jhrt2dav524 43 18 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 43 19 median median JJ work_ksthdbpq7vbwdm3jhrt2dav524 43 20 length length NN work_ksthdbpq7vbwdm3jhrt2dav524 43 21 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 43 22 maintenance maintenance NN work_ksthdbpq7vbwdm3jhrt2dav524 43 23 treatment treatment NN work_ksthdbpq7vbwdm3jhrt2dav524 43 24 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 43 25 54 54 CD work_ksthdbpq7vbwdm3jhrt2dav524 43 26 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 43 27 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 43 28 . . . work_ksthdbpq7vbwdm3jhrt2dav524 44 1 At at IN work_ksthdbpq7vbwdm3jhrt2dav524 44 2 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 44 3 end end NN work_ksthdbpq7vbwdm3jhrt2dav524 44 4 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 44 5 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 44 6 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 44 7 , , , work_ksthdbpq7vbwdm3jhrt2dav524 44 8 23 23 CD work_ksthdbpq7vbwdm3jhrt2dav524 44 9 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 44 10 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 44 11 82 82 CD work_ksthdbpq7vbwdm3jhrt2dav524 44 12 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 44 13 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 44 14 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 44 15 evaluable evaluable JJ work_ksthdbpq7vbwdm3jhrt2dav524 44 16 . . . work_ksthdbpq7vbwdm3jhrt2dav524 45 1 Five five CD work_ksthdbpq7vbwdm3jhrt2dav524 45 2 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 45 3 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 45 4 not not RB work_ksthdbpq7vbwdm3jhrt2dav524 45 5 evaluable evaluable JJ work_ksthdbpq7vbwdm3jhrt2dav524 45 6 owing owing NN work_ksthdbpq7vbwdm3jhrt2dav524 45 7 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 45 8 no no DT work_ksthdbpq7vbwdm3jhrt2dav524 45 9 postbase- postbase- NN work_ksthdbpq7vbwdm3jhrt2dav524 45 10 line line NN work_ksthdbpq7vbwdm3jhrt2dav524 45 11 assessment assessment NN work_ksthdbpq7vbwdm3jhrt2dav524 45 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 46 1 Reasons reason NNS work_ksthdbpq7vbwdm3jhrt2dav524 46 2 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 46 3 coming come VBG work_ksthdbpq7vbwdm3jhrt2dav524 46 4 off off RP work_ksthdbpq7vbwdm3jhrt2dav524 46 5 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 46 6 included include VBD work_ksthdbpq7vbwdm3jhrt2dav524 46 7 death death NN work_ksthdbpq7vbwdm3jhrt2dav524 46 8 caused cause VBN work_ksthdbpq7vbwdm3jhrt2dav524 46 9 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 46 10 progressive progressive JJ work_ksthdbpq7vbwdm3jhrt2dav524 46 11 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 46 12 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 46 13 n n NN work_ksthdbpq7vbwdm3jhrt2dav524 46 14 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 46 15 20 20 CD work_ksthdbpq7vbwdm3jhrt2dav524 46 16 [ [ -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 46 17 71 71 CD work_ksthdbpq7vbwdm3jhrt2dav524 46 18 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 46 19 ] ] -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 46 20 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 46 21 , , , work_ksthdbpq7vbwdm3jhrt2dav524 46 22 death death NN work_ksthdbpq7vbwdm3jhrt2dav524 46 23 caused cause VBN work_ksthdbpq7vbwdm3jhrt2dav524 46 24 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 46 25 other other JJ work_ksthdbpq7vbwdm3jhrt2dav524 46 26 reasons reason NNS work_ksthdbpq7vbwdm3jhrt2dav524 46 27 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 46 28 n n JJ work_ksthdbpq7vbwdm3jhrt2dav524 46 29 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 46 30 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 46 31 [ [ -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 46 32 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 46 33 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 46 34 ] ] -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 46 35 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 46 36 , , , work_ksthdbpq7vbwdm3jhrt2dav524 46 37 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 46 38 refusal refusal NN work_ksthdbpq7vbwdm3jhrt2dav524 46 39 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 46 40 fol- fol- VB work_ksthdbpq7vbwdm3jhrt2dav524 46 41 low low NN work_ksthdbpq7vbwdm3jhrt2dav524 46 42 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 46 43 up up NN work_ksthdbpq7vbwdm3jhrt2dav524 46 44 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 46 45 n n NN work_ksthdbpq7vbwdm3jhrt2dav524 46 46 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 46 47 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 46 48 [ [ -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 46 49 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 46 50 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 46 51 ] ] -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 46 52 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 46 53 . . . work_ksthdbpq7vbwdm3jhrt2dav524 47 1 Among among IN work_ksthdbpq7vbwdm3jhrt2dav524 47 2 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 47 3 28 28 CD work_ksthdbpq7vbwdm3jhrt2dav524 47 4 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 47 5 , , , work_ksthdbpq7vbwdm3jhrt2dav524 47 6 10 10 CD work_ksthdbpq7vbwdm3jhrt2dav524 47 7 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 47 8 36 36 CD work_ksthdbpq7vbwdm3jhrt2dav524 47 9 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 47 10 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 47 11 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 47 12 dose dose VBN work_ksthdbpq7vbwdm3jhrt2dav524 47 13 modification modification NN work_ksthdbpq7vbwdm3jhrt2dav524 47 14 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 47 15 16 16 CD work_ksthdbpq7vbwdm3jhrt2dav524 47 16 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 47 17 57 57 CD work_ksthdbpq7vbwdm3jhrt2dav524 47 18 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 47 19 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 47 20 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 47 21 dose dose VBN work_ksthdbpq7vbwdm3jhrt2dav524 47 22 delay delay NN work_ksthdbpq7vbwdm3jhrt2dav524 47 23 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 47 24 sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 47 25 . . . work_ksthdbpq7vbwdm3jhrt2dav524 48 1 Fifteen fifteen CD work_ksthdbpq7vbwdm3jhrt2dav524 48 2 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 48 3 54 54 CD work_ksthdbpq7vbwdm3jhrt2dav524 48 4 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 48 5 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 48 6 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 48 7 dose dose VBN work_ksthdbpq7vbwdm3jhrt2dav524 48 8 modification modification NN work_ksthdbpq7vbwdm3jhrt2dav524 48 9 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 48 10 paclitaxel paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 48 11 , , , work_ksthdbpq7vbwdm3jhrt2dav524 48 12 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 48 13 14 14 CD work_ksthdbpq7vbwdm3jhrt2dav524 48 14 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 48 15 50 50 CD work_ksthdbpq7vbwdm3jhrt2dav524 48 16 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 48 17 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 48 18 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 48 19 dose dose VBN work_ksthdbpq7vbwdm3jhrt2dav524 48 20 delay delay NN work_ksthdbpq7vbwdm3jhrt2dav524 48 21 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 48 22 paclitaxel paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 48 23 . . . work_ksthdbpq7vbwdm3jhrt2dav524 49 1 Toxicity toxicity NN work_ksthdbpq7vbwdm3jhrt2dav524 49 2 data datum NNS work_ksthdbpq7vbwdm3jhrt2dav524 49 3 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 49 4 all all DT work_ksthdbpq7vbwdm3jhrt2dav524 49 5 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 49 6 are be VBP work_ksthdbpq7vbwdm3jhrt2dav524 49 7 summarized summarize VBN work_ksthdbpq7vbwdm3jhrt2dav524 49 8 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 49 9 Tables Tables NNP work_ksthdbpq7vbwdm3jhrt2dav524 49 10 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 49 11 through through IN work_ksthdbpq7vbwdm3jhrt2dav524 49 12 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 49 13 . . . work_ksthdbpq7vbwdm3jhrt2dav524 50 1 The the DT work_ksthdbpq7vbwdm3jhrt2dav524 50 2 most most RBS work_ksthdbpq7vbwdm3jhrt2dav524 50 3 common common JJ work_ksthdbpq7vbwdm3jhrt2dav524 50 4 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 50 5 reported report VBD work_ksthdbpq7vbwdm3jhrt2dav524 50 6 included included JJ work_ksthdbpq7vbwdm3jhrt2dav524 50 7 fatigue fatigue NN work_ksthdbpq7vbwdm3jhrt2dav524 50 8 , , , work_ksthdbpq7vbwdm3jhrt2dav524 50 9 anemia anemia NN work_ksthdbpq7vbwdm3jhrt2dav524 50 10 , , , work_ksthdbpq7vbwdm3jhrt2dav524 50 11 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 50 12 leukopenia leukopenia NNP work_ksthdbpq7vbwdm3jhrt2dav524 50 13 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 50 14 neutropenia neutropenia NNP work_ksthdbpq7vbwdm3jhrt2dav524 50 15 . . . work_ksthdbpq7vbwdm3jhrt2dav524 51 1 Grade Grade NNP work_ksthdbpq7vbwdm3jhrt2dav524 51 2 3 3 CD work_ksthdbpq7vbwdm3jhrt2dav524 51 3 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 51 4 grade grade NN work_ksthdbpq7vbwdm3jhrt2dav524 51 5 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 51 6 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 51 7 included include VBD work_ksthdbpq7vbwdm3jhrt2dav524 51 8 leukopenia leukopenia NNP work_ksthdbpq7vbwdm3jhrt2dav524 51 9 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 51 10 neutropenia neutropenia NNP work_ksthdbpq7vbwdm3jhrt2dav524 51 11 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 51 12 25 25 CD work_ksthdbpq7vbwdm3jhrt2dav524 51 13 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 51 14 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 51 15 , , , work_ksthdbpq7vbwdm3jhrt2dav524 51 16 anemia anemia NN work_ksthdbpq7vbwdm3jhrt2dav524 51 17 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 51 18 18 18 CD work_ksthdbpq7vbwdm3jhrt2dav524 51 19 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 51 20 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 51 21 , , , work_ksthdbpq7vbwdm3jhrt2dav524 51 22 fatigue fatigue NN work_ksthdbpq7vbwdm3jhrt2dav524 51 23 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 51 24 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 51 25 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 51 26 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 51 27 , , , work_ksthdbpq7vbwdm3jhrt2dav524 51 28 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 51 29 hemorrhage hemorrhage NN work_ksthdbpq7vbwdm3jhrt2dav524 51 30 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 51 31 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 51 32 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 51 33 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 51 34 . . . work_ksthdbpq7vbwdm3jhrt2dav524 52 1 There there EX work_ksthdbpq7vbwdm3jhrt2dav524 52 2 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 52 3 four four CD work_ksthdbpq7vbwdm3jhrt2dav524 52 4 grade grade NN work_ksthdbpq7vbwdm3jhrt2dav524 52 5 5 5 CD work_ksthdbpq7vbwdm3jhrt2dav524 52 6 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 52 7 including include VBG work_ksthdbpq7vbwdm3jhrt2dav524 52 8 two two CD work_ksthdbpq7vbwdm3jhrt2dav524 52 9 deaths death NNS work_ksthdbpq7vbwdm3jhrt2dav524 52 10 caused cause VBN work_ksthdbpq7vbwdm3jhrt2dav524 52 11 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 52 12 upper upper JJ work_ksthdbpq7vbwdm3jhrt2dav524 52 13 gastrointestinal gastrointestinal JJ work_ksthdbpq7vbwdm3jhrt2dav524 52 14 hemorrhage hemorrhage NN work_ksthdbpq7vbwdm3jhrt2dav524 52 15 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 52 16 one one NN work_ksthdbpq7vbwdm3jhrt2dav524 52 17 caused cause VBN work_ksthdbpq7vbwdm3jhrt2dav524 52 18 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 52 19 gastro- gastro- NNP work_ksthdbpq7vbwdm3jhrt2dav524 52 20 intestinal intestinal JJ work_ksthdbpq7vbwdm3jhrt2dav524 52 21 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 52 22 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 52 23 fistula fistula NN work_ksthdbpq7vbwdm3jhrt2dav524 52 24 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 52 25 Table table NN work_ksthdbpq7vbwdm3jhrt2dav524 52 26 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 52 27 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 52 28 . . . work_ksthdbpq7vbwdm3jhrt2dav524 53 1 Three three CD work_ksthdbpq7vbwdm3jhrt2dav524 53 2 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 53 3 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 53 4 four four CD work_ksthdbpq7vbwdm3jhrt2dav524 53 5 events event NNS work_ksthdbpq7vbwdm3jhrt2dav524 53 6 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 53 7 considered consider VBN work_ksthdbpq7vbwdm3jhrt2dav524 53 8 treatment treatment NN work_ksthdbpq7vbwdm3jhrt2dav524 53 9 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 53 10 related relate VBN work_ksthdbpq7vbwdm3jhrt2dav524 53 11 deaths death NNS work_ksthdbpq7vbwdm3jhrt2dav524 53 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 54 1 Sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 54 2 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 54 3 related relate VBN work_ksthdbpq7vbwdm3jhrt2dav524 54 4 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 54 5 including include VBG work_ksthdbpq7vbwdm3jhrt2dav524 54 6 diarrhea diarrhea NN work_ksthdbpq7vbwdm3jhrt2dav524 54 7 , , , work_ksthdbpq7vbwdm3jhrt2dav524 54 8 rash rash NNP work_ksthdbpq7vbwdm3jhrt2dav524 54 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 54 10 hemorrhage hemorrhage NN work_ksthdbpq7vbwdm3jhrt2dav524 54 11 , , , work_ksthdbpq7vbwdm3jhrt2dav524 54 12 thrombosis thrombosis NN work_ksthdbpq7vbwdm3jhrt2dav524 54 13 , , , work_ksthdbpq7vbwdm3jhrt2dav524 54 14 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 54 15 hypertension hypertension NN work_ksthdbpq7vbwdm3jhrt2dav524 54 16 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 54 17 also also RB work_ksthdbpq7vbwdm3jhrt2dav524 54 18 observed observe VBN work_ksthdbpq7vbwdm3jhrt2dav524 54 19 . . . work_ksthdbpq7vbwdm3jhrt2dav524 55 1 The the DT work_ksthdbpq7vbwdm3jhrt2dav524 55 2 24-week 24-week CD work_ksthdbpq7vbwdm3jhrt2dav524 55 3 progression progression NN work_ksthdbpq7vbwdm3jhrt2dav524 55 4 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 55 5 free free JJ work_ksthdbpq7vbwdm3jhrt2dav524 55 6 survival survival NN work_ksthdbpq7vbwdm3jhrt2dav524 55 7 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 55 8 PFS PFS NNP work_ksthdbpq7vbwdm3jhrt2dav524 55 9 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 55 10 rate rate NN work_ksthdbpq7vbwdm3jhrt2dav524 55 11 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 55 12 25 25 CD work_ksthdbpq7vbwdm3jhrt2dav524 55 13 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 55 14 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 55 15 7/28 7/28 CD work_ksthdbpq7vbwdm3jhrt2dav524 55 16 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 55 17 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 55 18 90 90 CD work_ksthdbpq7vbwdm3jhrt2dav524 55 19 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 55 20 CI CI NNP work_ksthdbpq7vbwdm3jhrt2dav524 55 21 , , , work_ksthdbpq7vbwdm3jhrt2dav524 55 22 12–42 12–42 CD work_ksthdbpq7vbwdm3jhrt2dav524 55 23 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 55 24 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 55 25 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 55 26 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 55 27 combined combined JJ work_ksthdbpq7vbwdm3jhrt2dav524 55 28 regimen regiman NNS work_ksthdbpq7vbwdm3jhrt2dav524 55 29 . . . work_ksthdbpq7vbwdm3jhrt2dav524 56 1 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 56 2 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 56 3 23 23 CD work_ksthdbpq7vbwdm3jhrt2dav524 56 4 evaluable evaluable JJ work_ksthdbpq7vbwdm3jhrt2dav524 56 5 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 56 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 56 7 3 3 CD work_ksthdbpq7vbwdm3jhrt2dav524 56 8 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 56 9 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 56 10 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 56 11 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 56 12 had have VBD work_ksthdbpq7vbwdm3jhrt2dav524 56 13 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 56 14 measurable measurable JJ work_ksthdbpq7vbwdm3jhrt2dav524 56 15 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 56 16 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 56 17 RECIST RECIST NNP work_ksthdbpq7vbwdm3jhrt2dav524 56 18 criteria criterion NNS work_ksthdbpq7vbwdm3jhrt2dav524 56 19 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 56 20 90 90 CD work_ksthdbpq7vbwdm3jhrt2dav524 56 21 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 56 22 CI ci NN work_ksthdbpq7vbwdm3jhrt2dav524 56 23 , , , work_ksthdbpq7vbwdm3jhrt2dav524 56 24 3−25 3−25 CD work_ksthdbpq7vbwdm3jhrt2dav524 56 25 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 56 26 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 56 27 . . . work_ksthdbpq7vbwdm3jhrt2dav524 57 1 A a DT work_ksthdbpq7vbwdm3jhrt2dav524 57 2 complete complete JJ work_ksthdbpq7vbwdm3jhrt2dav524 57 3 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 57 4 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 57 5 observed observe VBN work_ksthdbpq7vbwdm3jhrt2dav524 57 6 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 57 7 one one CD work_ksthdbpq7vbwdm3jhrt2dav524 57 8 patient patient JJ work_ksthdbpq7vbwdm3jhrt2dav524 57 9 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 57 10 partial partial JJ work_ksthdbpq7vbwdm3jhrt2dav524 57 11 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 57 12 observed observe VBN work_ksthdbpq7vbwdm3jhrt2dav524 57 13 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 57 14 two two CD work_ksthdbpq7vbwdm3jhrt2dav524 57 15 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 57 16 . . . work_ksthdbpq7vbwdm3jhrt2dav524 58 1 For for IN work_ksthdbpq7vbwdm3jhrt2dav524 58 2 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 58 3 three three CD work_ksthdbpq7vbwdm3jhrt2dav524 58 4 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 58 5 who who WP work_ksthdbpq7vbwdm3jhrt2dav524 58 6 responded respond VBD work_ksthdbpq7vbwdm3jhrt2dav524 58 7 , , , work_ksthdbpq7vbwdm3jhrt2dav524 58 8 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 58 9 dura- dura- JJ work_ksthdbpq7vbwdm3jhrt2dav524 58 10 tions tion NNS work_ksthdbpq7vbwdm3jhrt2dav524 58 11 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 58 12 response response NN work_ksthdbpq7vbwdm3jhrt2dav524 58 13 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 58 14 29 29 CD work_ksthdbpq7vbwdm3jhrt2dav524 58 15 , , , work_ksthdbpq7vbwdm3jhrt2dav524 58 16 56 56 CD work_ksthdbpq7vbwdm3jhrt2dav524 58 17 , , , work_ksthdbpq7vbwdm3jhrt2dav524 58 18 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 58 19 72 72 CD work_ksthdbpq7vbwdm3jhrt2dav524 58 20 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 58 21 , , , work_ksthdbpq7vbwdm3jhrt2dav524 58 22 respectively respectively RB work_ksthdbpq7vbwdm3jhrt2dav524 58 23 . . . work_ksthdbpq7vbwdm3jhrt2dav524 59 1 For for IN work_ksthdbpq7vbwdm3jhrt2dav524 59 2 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 59 3 28 28 CD work_ksthdbpq7vbwdm3jhrt2dav524 59 4 intention intention NN work_ksthdbpq7vbwdm3jhrt2dav524 59 5 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 59 6 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 59 7 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 59 8 treat treat NN work_ksthdbpq7vbwdm3jhrt2dav524 59 9 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 59 10 , , , work_ksthdbpq7vbwdm3jhrt2dav524 59 11 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 59 12 1-year 1-year CD work_ksthdbpq7vbwdm3jhrt2dav524 59 13 overall overall JJ work_ksthdbpq7vbwdm3jhrt2dav524 59 14 survival survival NN work_ksthdbpq7vbwdm3jhrt2dav524 59 15 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 59 16 oS oS NNP work_ksthdbpq7vbwdm3jhrt2dav524 59 17 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 59 18 rate rate NN work_ksthdbpq7vbwdm3jhrt2dav524 59 19 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 59 20 20 20 CD work_ksthdbpq7vbwdm3jhrt2dav524 59 21 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 59 22 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 59 23 90 90 CD work_ksthdbpq7vbwdm3jhrt2dav524 59 24 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 59 25 CI CI NNP work_ksthdbpq7vbwdm3jhrt2dav524 59 26 , , , work_ksthdbpq7vbwdm3jhrt2dav524 59 27 9−34 9−34 CD work_ksthdbpq7vbwdm3jhrt2dav524 59 28 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 59 29 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 59 30 . . . work_ksthdbpq7vbwdm3jhrt2dav524 60 1 Median Median NNP work_ksthdbpq7vbwdm3jhrt2dav524 60 2 oS oS NNP work_ksthdbpq7vbwdm3jhrt2dav524 60 3 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 60 4 228 228 CD work_ksthdbpq7vbwdm3jhrt2dav524 60 5 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 60 6 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 60 7 90 90 CD work_ksthdbpq7vbwdm3jhrt2dav524 60 8 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 60 9 CI CI NNP work_ksthdbpq7vbwdm3jhrt2dav524 60 10 , , , work_ksthdbpq7vbwdm3jhrt2dav524 60 11 140–283 140–283 CD work_ksthdbpq7vbwdm3jhrt2dav524 60 12 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 60 13 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 60 14 . . . work_ksthdbpq7vbwdm3jhrt2dav524 61 1 The the DT work_ksthdbpq7vbwdm3jhrt2dav524 61 2 median median JJ work_ksthdbpq7vbwdm3jhrt2dav524 61 3 PFS PFS NNP work_ksthdbpq7vbwdm3jhrt2dav524 61 4 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 61 5 112 112 CD work_ksthdbpq7vbwdm3jhrt2dav524 61 6 days day NNS work_ksthdbpq7vbwdm3jhrt2dav524 61 7 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 61 8 90 90 CD work_ksthdbpq7vbwdm3jhrt2dav524 61 9 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 61 10 CI CI NNP work_ksthdbpq7vbwdm3jhrt2dav524 61 11 , , , work_ksthdbpq7vbwdm3jhrt2dav524 61 12 54–150 54–150 CD work_ksthdbpq7vbwdm3jhrt2dav524 61 13 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 61 14 . . . work_ksthdbpq7vbwdm3jhrt2dav524 62 1 TABLE TABLE NNP work_ksthdbpq7vbwdm3jhrt2dav524 62 2 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 62 3 . . . work_ksthdbpq7vbwdm3jhrt2dav524 63 1 Demographics demographic NNS work_ksthdbpq7vbwdm3jhrt2dav524 63 2 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 63 3 Intention intention NN work_ksthdbpq7vbwdm3jhrt2dav524 63 4 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 63 5 Treat Treat NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 6 n n CC work_ksthdbpq7vbwdm3jhrt2dav524 63 7 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 63 8 28 28 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 9 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 63 10 Characteristics Characteristics NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 11 Category/ Category/ NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 12 Statistics Statistics NNPS work_ksthdbpq7vbwdm3jhrt2dav524 63 13 n n CC work_ksthdbpq7vbwdm3jhrt2dav524 63 14 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 63 15 Value value NN work_ksthdbpq7vbwdm3jhrt2dav524 63 16 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 63 17 Sex sex NN work_ksthdbpq7vbwdm3jhrt2dav524 63 18 Female female NN work_ksthdbpq7vbwdm3jhrt2dav524 63 19 5 5 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 20 18 18 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 21 Male male NN work_ksthdbpq7vbwdm3jhrt2dav524 63 22 23 23 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 23 82 82 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 24 Race Race NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 25 Caucasian caucasian JJ work_ksthdbpq7vbwdm3jhrt2dav524 63 26 27 27 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 27 96 96 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 28 African african JJ work_ksthdbpq7vbwdm3jhrt2dav524 63 29 American American NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 30 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 31 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 32 Ethnicity Ethnicity NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 33 Non non JJ work_ksthdbpq7vbwdm3jhrt2dav524 63 34 - - JJ work_ksthdbpq7vbwdm3jhrt2dav524 63 35 Hispanic hispanic JJ work_ksthdbpq7vbwdm3jhrt2dav524 63 36 27 27 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 37 96 96 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 38 Not not RB work_ksthdbpq7vbwdm3jhrt2dav524 63 39 reported report VBN work_ksthdbpq7vbwdm3jhrt2dav524 63 40 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 41 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 42 Age Age NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 43 Median Median NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 44 59.5 59.5 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 45 yr yr NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 46 Range Range NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 47 40–84 40–84 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 48 yr yr NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 49 ECoG ECoG NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 50 PS PS NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 51 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 52 15 15 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 53 54 54 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 54 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 55 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 56 39 39 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 57 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 58 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 59 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 60 Tumor Tumor NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 61 site site NN work_ksthdbpq7vbwdm3jhrt2dav524 63 62 Esophagus Esophagus NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 63 22 22 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 64 79 79 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 65 Gastroesophageal Gastroesophageal NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 66 junction junction NN work_ksthdbpq7vbwdm3jhrt2dav524 63 67 6 6 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 68 21 21 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 69 Histology Histology NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 70 Adenocarcinoma Adenocarcinoma NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 71 26 26 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 72 93 93 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 73 Squamous squamous JJ work_ksthdbpq7vbwdm3jhrt2dav524 63 74 cell cell NN work_ksthdbpq7vbwdm3jhrt2dav524 63 75 carcinoma carcinoma NN work_ksthdbpq7vbwdm3jhrt2dav524 63 76 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 77 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 78 Prior prior JJ work_ksthdbpq7vbwdm3jhrt2dav524 63 79 treatment treatment NN work_ksthdbpq7vbwdm3jhrt2dav524 63 80 Yes yes NN work_ksthdbpq7vbwdm3jhrt2dav524 63 81 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 82 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 63 83 9 9 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 84 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 63 85 prior prior JJ work_ksthdbpq7vbwdm3jhrt2dav524 63 86 chemo chemo NN work_ksthdbpq7vbwdm3jhrt2dav524 63 87 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 63 88 39 39 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 89 No no DT work_ksthdbpq7vbwdm3jhrt2dav524 63 90 17 17 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 91 61 61 CD work_ksthdbpq7vbwdm3jhrt2dav524 63 92 ECoG ECoG NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 93 PS PS NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 94 , , , work_ksthdbpq7vbwdm3jhrt2dav524 63 95 Eastern Eastern NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 96 Cooperative Cooperative NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 97 oncology oncology NN work_ksthdbpq7vbwdm3jhrt2dav524 63 98 Group Group NNP work_ksthdbpq7vbwdm3jhrt2dav524 63 99 performance performance NN work_ksthdbpq7vbwdm3jhrt2dav524 63 100 status status NN work_ksthdbpq7vbwdm3jhrt2dav524 63 101 . . . work_ksthdbpq7vbwdm3jhrt2dav524 64 1 TABLE TABLE NNP work_ksthdbpq7vbwdm3jhrt2dav524 64 2 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 64 3 . . . work_ksthdbpq7vbwdm3jhrt2dav524 65 1 Selected select VBN work_ksthdbpq7vbwdm3jhrt2dav524 65 2 Hematologic Hematologic NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 3 Toxicities Toxicities NNPS work_ksthdbpq7vbwdm3jhrt2dav524 65 4 Irrespective irrespective JJ work_ksthdbpq7vbwdm3jhrt2dav524 65 5 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 65 6 Causality Causality NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 7 Attributed attribute VBN work_ksthdbpq7vbwdm3jhrt2dav524 65 8 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 65 9 n n CC work_ksthdbpq7vbwdm3jhrt2dav524 65 10 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 65 11 28 28 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 12 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 65 13 Grade Grade NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 14 3 3 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 15 Grade Grade NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 16 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 17 Grade Grade NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 18 3/4 3/4 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 19 Leukopenia Leukopenia NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 20 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 65 21 neutropenia neutropenia NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 22 6 6 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 23 21 21 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 24 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 65 25 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 26 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 27 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 65 28 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 29 25 25 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 30 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 65 31 Anemia Anemia NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 32 3 3 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 33 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 34 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 65 35 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 36 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 37 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 65 38 5 5 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 39 18 18 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 40 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 65 41 Thrombocytopenia Thrombocytopenia NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 42 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 43 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 44 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 65 45 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 46 — — SYM work_ksthdbpq7vbwdm3jhrt2dav524 65 47 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 48 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 49 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 65 50 Febrile Febrile NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 51 neutropenia neutropenia NN work_ksthdbpq7vbwdm3jhrt2dav524 65 52 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 65 53 fever fever NN work_ksthdbpq7vbwdm3jhrt2dav524 65 54 without without IN work_ksthdbpq7vbwdm3jhrt2dav524 65 55 clinically clinically RB work_ksthdbpq7vbwdm3jhrt2dav524 65 56 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 65 57 microbiologically microbiologically RB work_ksthdbpq7vbwdm3jhrt2dav524 65 58 documented document VBN work_ksthdbpq7vbwdm3jhrt2dav524 65 59 infection infection NN work_ksthdbpq7vbwdm3jhrt2dav524 65 60 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 65 61 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 65 62 ANC ANC NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 63 < < XX work_ksthdbpq7vbwdm3jhrt2dav524 65 64 1.0 1.0 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 65 , , , work_ksthdbpq7vbwdm3jhrt2dav524 65 66 fever fever NN work_ksthdbpq7vbwdm3jhrt2dav524 65 67 ≥38.5 ≥38.5 NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 68 ° ° , work_ksthdbpq7vbwdm3jhrt2dav524 65 69 C C NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 70 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 65 71 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 72 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 73 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 65 74 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 75 — — SYM work_ksthdbpq7vbwdm3jhrt2dav524 65 76 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 77 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 65 78 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 65 79 ANC ANC NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 80 , , , work_ksthdbpq7vbwdm3jhrt2dav524 65 81 absolute absolute JJ work_ksthdbpq7vbwdm3jhrt2dav524 65 82 neutrophil neutrophil NNP work_ksthdbpq7vbwdm3jhrt2dav524 65 83 count count NN work_ksthdbpq7vbwdm3jhrt2dav524 65 84 . . . work_ksthdbpq7vbwdm3jhrt2dav524 66 1 762 762 CD work_ksthdbpq7vbwdm3jhrt2dav524 66 2 Copyright copyright NN work_ksthdbpq7vbwdm3jhrt2dav524 66 3 © © NN work_ksthdbpq7vbwdm3jhrt2dav524 66 4 2012 2012 CD work_ksthdbpq7vbwdm3jhrt2dav524 66 5 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 66 6 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 66 7 International International NNP work_ksthdbpq7vbwdm3jhrt2dav524 66 8 Association Association NNP work_ksthdbpq7vbwdm3jhrt2dav524 66 9 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 66 10 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 66 11 Study Study NNP work_ksthdbpq7vbwdm3jhrt2dav524 66 12 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 66 13 Lung Lung NNP work_ksthdbpq7vbwdm3jhrt2dav524 66 14 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 66 15 Schmitt Schmitt NNP work_ksthdbpq7vbwdm3jhrt2dav524 66 16 et et FW work_ksthdbpq7vbwdm3jhrt2dav524 66 17 al al NNP work_ksthdbpq7vbwdm3jhrt2dav524 66 18 . . . work_ksthdbpq7vbwdm3jhrt2dav524 67 1 Journal Journal NNP work_ksthdbpq7vbwdm3jhrt2dav524 67 2 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 67 3 Thoracic Thoracic NNP work_ksthdbpq7vbwdm3jhrt2dav524 67 4 Oncology Oncology NNP work_ksthdbpq7vbwdm3jhrt2dav524 67 5 • • NNP work_ksthdbpq7vbwdm3jhrt2dav524 67 6 Volume volume NN work_ksthdbpq7vbwdm3jhrt2dav524 67 7 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 67 8 , , , work_ksthdbpq7vbwdm3jhrt2dav524 67 9 Number number NN work_ksthdbpq7vbwdm3jhrt2dav524 67 10 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 67 11 , , , work_ksthdbpq7vbwdm3jhrt2dav524 67 12 April April NNP work_ksthdbpq7vbwdm3jhrt2dav524 67 13 2012 2012 CD work_ksthdbpq7vbwdm3jhrt2dav524 67 14 DISCUSSION discussion NN work_ksthdbpq7vbwdm3jhrt2dav524 67 15 The the DT work_ksthdbpq7vbwdm3jhrt2dav524 67 16 results result NNS work_ksthdbpq7vbwdm3jhrt2dav524 67 17 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 67 18 this this DT work_ksthdbpq7vbwdm3jhrt2dav524 67 19 multi multi JJ work_ksthdbpq7vbwdm3jhrt2dav524 67 20 - - JJ work_ksthdbpq7vbwdm3jhrt2dav524 67 21 institutional institutional JJ work_ksthdbpq7vbwdm3jhrt2dav524 67 22 phase phase NN work_ksthdbpq7vbwdm3jhrt2dav524 67 23 II II NNP work_ksthdbpq7vbwdm3jhrt2dav524 67 24 trial trial NN work_ksthdbpq7vbwdm3jhrt2dav524 67 25 are be VBP work_ksthdbpq7vbwdm3jhrt2dav524 67 26 , , , work_ksthdbpq7vbwdm3jhrt2dav524 67 27 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 67 28 our -PRON- PRP$ work_ksthdbpq7vbwdm3jhrt2dav524 67 29 knowledge knowledge NN work_ksthdbpq7vbwdm3jhrt2dav524 67 30 , , , work_ksthdbpq7vbwdm3jhrt2dav524 67 31 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 67 32 first first JJ work_ksthdbpq7vbwdm3jhrt2dav524 67 33 reported report VBN work_ksthdbpq7vbwdm3jhrt2dav524 67 34 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 67 35 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 67 36 sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 67 37 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 67 38 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 67 39 esophageal esophageal NN work_ksthdbpq7vbwdm3jhrt2dav524 67 40 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 67 41 GE GE NNP work_ksthdbpq7vbwdm3jhrt2dav524 67 42 junction junction NN work_ksthdbpq7vbwdm3jhrt2dav524 67 43 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 67 44 . . . work_ksthdbpq7vbwdm3jhrt2dav524 68 1 This this DT work_ksthdbpq7vbwdm3jhrt2dav524 68 2 combination combination NN work_ksthdbpq7vbwdm3jhrt2dav524 68 3 did do VBD work_ksthdbpq7vbwdm3jhrt2dav524 68 4 not not RB work_ksthdbpq7vbwdm3jhrt2dav524 68 5 meet meet VB work_ksthdbpq7vbwdm3jhrt2dav524 68 6 our -PRON- PRP$ work_ksthdbpq7vbwdm3jhrt2dav524 68 7 predetermined predetermine VBN work_ksthdbpq7vbwdm3jhrt2dav524 68 8 goal goal NN work_ksthdbpq7vbwdm3jhrt2dav524 68 9 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 68 10 improved improved JJ work_ksthdbpq7vbwdm3jhrt2dav524 68 11 nonprogres- nonprogres- NN work_ksthdbpq7vbwdm3jhrt2dav524 68 12 sive sive JJ work_ksthdbpq7vbwdm3jhrt2dav524 68 13 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 68 14 from from IN work_ksthdbpq7vbwdm3jhrt2dav524 68 15 25 25 CD work_ksthdbpq7vbwdm3jhrt2dav524 68 16 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 68 17 50 50 CD work_ksthdbpq7vbwdm3jhrt2dav524 68 18 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 68 19 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 68 20 24 24 CD work_ksthdbpq7vbwdm3jhrt2dav524 68 21 weeks week NNS work_ksthdbpq7vbwdm3jhrt2dav524 68 22 . . . work_ksthdbpq7vbwdm3jhrt2dav524 69 1 The the DT work_ksthdbpq7vbwdm3jhrt2dav524 69 2 majority majority NN work_ksthdbpq7vbwdm3jhrt2dav524 69 3 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 69 4 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 69 5 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 69 6 completed complete VBD work_ksthdbpq7vbwdm3jhrt2dav524 69 7 less less JJR work_ksthdbpq7vbwdm3jhrt2dav524 69 8 than than IN work_ksthdbpq7vbwdm3jhrt2dav524 69 9 two two CD work_ksthdbpq7vbwdm3jhrt2dav524 69 10 cycles cycle NNS work_ksthdbpq7vbwdm3jhrt2dav524 69 11 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 69 12 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 69 13 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 69 14 significant significant JJ work_ksthdbpq7vbwdm3jhrt2dav524 69 15 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 69 16 at at RB work_ksthdbpq7vbwdm3jhrt2dav524 69 17 least least RBS work_ksthdbpq7vbwdm3jhrt2dav524 69 18 three three CD work_ksthdbpq7vbwdm3jhrt2dav524 69 19 treatment treatment NN work_ksthdbpq7vbwdm3jhrt2dav524 69 20 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 69 21 related relate VBN work_ksthdbpq7vbwdm3jhrt2dav524 69 22 deaths death NNS work_ksthdbpq7vbwdm3jhrt2dav524 69 23 . . . work_ksthdbpq7vbwdm3jhrt2dav524 70 1 Paclitaxel Paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 70 2 alone alone RB work_ksthdbpq7vbwdm3jhrt2dav524 70 3 as as IN work_ksthdbpq7vbwdm3jhrt2dav524 70 4 first first JJ work_ksthdbpq7vbwdm3jhrt2dav524 70 5 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 70 6 line line NN work_ksthdbpq7vbwdm3jhrt2dav524 70 7 therapy therapy NN work_ksthdbpq7vbwdm3jhrt2dav524 70 8 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 70 9 metastatic metastatic JJ work_ksthdbpq7vbwdm3jhrt2dav524 70 10 disease disease NN work_ksthdbpq7vbwdm3jhrt2dav524 70 11 has have VBZ work_ksthdbpq7vbwdm3jhrt2dav524 70 12 demonstrated demonstrate VBN work_ksthdbpq7vbwdm3jhrt2dav524 70 13 an an DT work_ksthdbpq7vbwdm3jhrt2dav524 70 14 RR rr NN work_ksthdbpq7vbwdm3jhrt2dav524 70 15 ranging range VBG work_ksthdbpq7vbwdm3jhrt2dav524 70 16 from from IN work_ksthdbpq7vbwdm3jhrt2dav524 70 17 15 15 CD work_ksthdbpq7vbwdm3jhrt2dav524 70 18 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 70 19 32 32 CD work_ksthdbpq7vbwdm3jhrt2dav524 70 20 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 70 21 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 70 22 two two CD work_ksthdbpq7vbwdm3jhrt2dav524 70 23 prior prior JJ work_ksthdbpq7vbwdm3jhrt2dav524 70 24 phase phase NN work_ksthdbpq7vbwdm3jhrt2dav524 70 25 II II NNP work_ksthdbpq7vbwdm3jhrt2dav524 70 26 studies study NNS work_ksthdbpq7vbwdm3jhrt2dav524 70 27 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 70 28 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 70 29 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 70 30 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 70 31 esophageal esophageal NN work_ksthdbpq7vbwdm3jhrt2dav524 70 32 cancer.9,10 cancer.9,10 . work_ksthdbpq7vbwdm3jhrt2dav524 70 33 This this DT work_ksthdbpq7vbwdm3jhrt2dav524 70 34 is be VBZ work_ksthdbpq7vbwdm3jhrt2dav524 70 35 inferior inferior JJ work_ksthdbpq7vbwdm3jhrt2dav524 70 36 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 70 37 RRs rr NNS work_ksthdbpq7vbwdm3jhrt2dav524 70 38 reported report VBN work_ksthdbpq7vbwdm3jhrt2dav524 70 39 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 70 40 use use NN work_ksthdbpq7vbwdm3jhrt2dav524 70 41 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 70 42 regimens regimen NNS work_ksthdbpq7vbwdm3jhrt2dav524 70 43 such such JJ work_ksthdbpq7vbwdm3jhrt2dav524 70 44 as as IN work_ksthdbpq7vbwdm3jhrt2dav524 70 45 epirubicin epirubicin NNS work_ksthdbpq7vbwdm3jhrt2dav524 70 46 + + SYM work_ksthdbpq7vbwdm3jhrt2dav524 70 47 cisplatin cisplatin NN work_ksthdbpq7vbwdm3jhrt2dav524 70 48 + + CC work_ksthdbpq7vbwdm3jhrt2dav524 70 49 fluorouracil fluorouracil NN work_ksthdbpq7vbwdm3jhrt2dav524 70 50 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 70 51 epirubicin epirubicin NN work_ksthdbpq7vbwdm3jhrt2dav524 70 52 + + CC work_ksthdbpq7vbwdm3jhrt2dav524 70 53 oxaliplatin oxaliplatin NN work_ksthdbpq7vbwdm3jhrt2dav524 70 54 + + CC work_ksthdbpq7vbwdm3jhrt2dav524 70 55 capecitabine capecitabine NN work_ksthdbpq7vbwdm3jhrt2dav524 70 56 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 70 57 paclitaxel paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 70 58 containing contain VBG work_ksthdbpq7vbwdm3jhrt2dav524 70 59 combination combination NN work_ksthdbpq7vbwdm3jhrt2dav524 70 60 regimens regimen VBZ work_ksthdbpq7vbwdm3jhrt2dav524 70 61 that that WDT work_ksthdbpq7vbwdm3jhrt2dav524 70 62 have have VBP work_ksthdbpq7vbwdm3jhrt2dav524 70 63 yielded yield VBN work_ksthdbpq7vbwdm3jhrt2dav524 70 64 higher high JJR work_ksthdbpq7vbwdm3jhrt2dav524 70 65 RRs rr NNS work_ksthdbpq7vbwdm3jhrt2dav524 70 66 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 70 67 40–54 40–54 CD work_ksthdbpq7vbwdm3jhrt2dav524 70 68 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 70 69 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 70 70 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 70 71 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 70 72 expense expense NN work_ksthdbpq7vbwdm3jhrt2dav524 70 73 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 70 74 higher high JJR work_ksthdbpq7vbwdm3jhrt2dav524 70 75 toxicity toxicity NN work_ksthdbpq7vbwdm3jhrt2dav524 70 76 rates rate NNS work_ksthdbpq7vbwdm3jhrt2dav524 70 77 , , , work_ksthdbpq7vbwdm3jhrt2dav524 70 78 including include VBG work_ksthdbpq7vbwdm3jhrt2dav524 70 79 docetaxel docetaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 70 80 + + SYM work_ksthdbpq7vbwdm3jhrt2dav524 70 81 cisplatin cisplatin NN work_ksthdbpq7vbwdm3jhrt2dav524 70 82 + + CC work_ksthdbpq7vbwdm3jhrt2dav524 70 83 5-fluorouracil,11 5-fluorouracil,11 NN work_ksthdbpq7vbwdm3jhrt2dav524 70 84 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 70 85 oxaliplatin oxaliplatin NN work_ksthdbpq7vbwdm3jhrt2dav524 70 86 + + CC work_ksthdbpq7vbwdm3jhrt2dav524 70 87 paclitaxel.12 paclitaxel.12 NNP work_ksthdbpq7vbwdm3jhrt2dav524 70 88 our -PRON- PRP$ work_ksthdbpq7vbwdm3jhrt2dav524 70 89 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 70 90 failed fail VBD work_ksthdbpq7vbwdm3jhrt2dav524 70 91 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 70 92 show show VB work_ksthdbpq7vbwdm3jhrt2dav524 70 93 similar similar JJ work_ksthdbpq7vbwdm3jhrt2dav524 70 94 RRs rr NNS work_ksthdbpq7vbwdm3jhrt2dav524 70 95 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 70 96 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 70 97 reported report VBN work_ksthdbpq7vbwdm3jhrt2dav524 70 98 overall overall JJ work_ksthdbpq7vbwdm3jhrt2dav524 70 99 RR rr NN work_ksthdbpq7vbwdm3jhrt2dav524 70 100 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 70 101 only only RB work_ksthdbpq7vbwdm3jhrt2dav524 70 102 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 70 103 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 70 104 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 70 105 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 70 106 24-week 24-week CD work_ksthdbpq7vbwdm3jhrt2dav524 70 107 PFS PFS NNP work_ksthdbpq7vbwdm3jhrt2dav524 70 108 rate rate NN work_ksthdbpq7vbwdm3jhrt2dav524 70 109 estimated estimate VBN work_ksthdbpq7vbwdm3jhrt2dav524 70 110 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 70 111 25 25 CD work_ksthdbpq7vbwdm3jhrt2dav524 70 112 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 70 113 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 70 114 increased increased JJ work_ksthdbpq7vbwdm3jhrt2dav524 70 115 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 70 116 . . . work_ksthdbpq7vbwdm3jhrt2dav524 71 1 VEGF vegf NN work_ksthdbpq7vbwdm3jhrt2dav524 71 2 inhibitors inhibitor NNS work_ksthdbpq7vbwdm3jhrt2dav524 71 3 have have VBP work_ksthdbpq7vbwdm3jhrt2dav524 71 4 been be VBN work_ksthdbpq7vbwdm3jhrt2dav524 71 5 studied study VBN work_ksthdbpq7vbwdm3jhrt2dav524 71 6 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 71 7 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 71 8 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 71 9 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 71 10 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 71 11 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 71 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 72 1 In in IN work_ksthdbpq7vbwdm3jhrt2dav524 72 2 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 72 3 phase phase NN work_ksthdbpq7vbwdm3jhrt2dav524 72 4 II ii CD work_ksthdbpq7vbwdm3jhrt2dav524 72 5 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 72 6 combining combine VBG work_ksthdbpq7vbwdm3jhrt2dav524 72 7 irino- irino- NNP work_ksthdbpq7vbwdm3jhrt2dav524 72 8 tecan tecan NNP work_ksthdbpq7vbwdm3jhrt2dav524 72 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 72 10 cisplatin cisplatin NNP work_ksthdbpq7vbwdm3jhrt2dav524 72 11 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 72 12 bevacizumab,13 bevacizumab,13 NNP work_ksthdbpq7vbwdm3jhrt2dav524 72 13 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 72 14 65 65 CD work_ksthdbpq7vbwdm3jhrt2dav524 72 15 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 72 16 overall overall JJ work_ksthdbpq7vbwdm3jhrt2dav524 72 17 RR rr NN work_ksthdbpq7vbwdm3jhrt2dav524 72 18 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 72 19 noted note VBN work_ksthdbpq7vbwdm3jhrt2dav524 72 20 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 72 21 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 72 22 median median JJ work_ksthdbpq7vbwdm3jhrt2dav524 72 23 time time NN work_ksthdbpq7vbwdm3jhrt2dav524 72 24 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 72 25 progression progression NN work_ksthdbpq7vbwdm3jhrt2dav524 72 26 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 72 27 8.3 8.3 CD work_ksthdbpq7vbwdm3jhrt2dav524 72 28 months month NNS work_ksthdbpq7vbwdm3jhrt2dav524 72 29 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 72 30 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 72 31 median median JJ work_ksthdbpq7vbwdm3jhrt2dav524 72 32 survival survival NN work_ksthdbpq7vbwdm3jhrt2dav524 72 33 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 72 34 12.3 12.3 CD work_ksthdbpq7vbwdm3jhrt2dav524 72 35 months month NNS work_ksthdbpq7vbwdm3jhrt2dav524 72 36 . . . work_ksthdbpq7vbwdm3jhrt2dav524 73 1 A a DT work_ksthdbpq7vbwdm3jhrt2dav524 73 2 second second JJ work_ksthdbpq7vbwdm3jhrt2dav524 73 3 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 73 4 looking look VBG work_ksthdbpq7vbwdm3jhrt2dav524 73 5 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 73 6 docetaxel docetaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 73 7 + + CC work_ksthdbpq7vbwdm3jhrt2dav524 73 8 cisplatin cisplatin NN work_ksthdbpq7vbwdm3jhrt2dav524 73 9 + + CC work_ksthdbpq7vbwdm3jhrt2dav524 73 10 5-FU 5-fu CD work_ksthdbpq7vbwdm3jhrt2dav524 73 11 + + SYM work_ksthdbpq7vbwdm3jhrt2dav524 73 12 bevacizumab bevacizumab NNS work_ksthdbpq7vbwdm3jhrt2dav524 73 13 demonstrated demonstrate VBD work_ksthdbpq7vbwdm3jhrt2dav524 73 14 an an DT work_ksthdbpq7vbwdm3jhrt2dav524 73 15 improvement improvement NN work_ksthdbpq7vbwdm3jhrt2dav524 73 16 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 73 17 PFS PFS NNP work_ksthdbpq7vbwdm3jhrt2dav524 73 18 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 73 19 6 6 CD work_ksthdbpq7vbwdm3jhrt2dav524 73 20 months month NNS work_ksthdbpq7vbwdm3jhrt2dav524 73 21 from from IN work_ksthdbpq7vbwdm3jhrt2dav524 73 22 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 73 23 historic historic JJ work_ksthdbpq7vbwdm3jhrt2dav524 73 24 control control NN work_ksthdbpq7vbwdm3jhrt2dav524 73 25 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 73 26 43 43 CD work_ksthdbpq7vbwdm3jhrt2dav524 73 27 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 73 28 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 73 29 docetaxel docetaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 73 30 + + SYM work_ksthdbpq7vbwdm3jhrt2dav524 73 31 cisplatin cisplatin NN work_ksthdbpq7vbwdm3jhrt2dav524 73 32 + + SYM work_ksthdbpq7vbwdm3jhrt2dav524 73 33 fluorouracil fluorouracil NN work_ksthdbpq7vbwdm3jhrt2dav524 73 34 alone alone RB work_ksthdbpq7vbwdm3jhrt2dav524 73 35 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 73 36 79 79 CD work_ksthdbpq7vbwdm3jhrt2dav524 73 37 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 73 38 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 73 39 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 73 40 addition addition NN work_ksthdbpq7vbwdm3jhrt2dav524 73 41 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 73 42 beva- beva- JJ work_ksthdbpq7vbwdm3jhrt2dav524 73 43 cizumab.14 cizumab.14 NNP work_ksthdbpq7vbwdm3jhrt2dav524 73 44 Grade Grade NNP work_ksthdbpq7vbwdm3jhrt2dav524 73 45 3 3 CD work_ksthdbpq7vbwdm3jhrt2dav524 73 46 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 73 47 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 73 48 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 73 49 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 73 50 both both DT work_ksthdbpq7vbwdm3jhrt2dav524 73 51 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 73 52 these these DT work_ksthdbpq7vbwdm3jhrt2dav524 73 53 studies study NNS work_ksthdbpq7vbwdm3jhrt2dav524 73 54 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 73 55 fewer few JJR work_ksthdbpq7vbwdm3jhrt2dav524 73 56 than than IN work_ksthdbpq7vbwdm3jhrt2dav524 73 57 appreciated appreciate VBN work_ksthdbpq7vbwdm3jhrt2dav524 73 58 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 73 59 our -PRON- PRP$ work_ksthdbpq7vbwdm3jhrt2dav524 73 60 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 73 61 . . . work_ksthdbpq7vbwdm3jhrt2dav524 74 1 Another another DT work_ksthdbpq7vbwdm3jhrt2dav524 74 2 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 74 3 evaluating evaluate VBG work_ksthdbpq7vbwdm3jhrt2dav524 74 4 bevacizumab bevacizumab NN work_ksthdbpq7vbwdm3jhrt2dav524 74 5 + + CC work_ksthdbpq7vbwdm3jhrt2dav524 74 6 cisplatin cisplatin NN work_ksthdbpq7vbwdm3jhrt2dav524 74 7 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 74 8 capecitabine capecitabine NN work_ksthdbpq7vbwdm3jhrt2dav524 74 9 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 74 10 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 74 11 gastric gastric JJ work_ksthdbpq7vbwdm3jhrt2dav524 74 12 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 74 13 reported report VBD work_ksthdbpq7vbwdm3jhrt2dav524 74 14 fewer few JJR work_ksthdbpq7vbwdm3jhrt2dav524 74 15 serious serious JJ work_ksthdbpq7vbwdm3jhrt2dav524 74 16 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 74 17 than than IN work_ksthdbpq7vbwdm3jhrt2dav524 74 18 observed observe VBN work_ksthdbpq7vbwdm3jhrt2dav524 74 19 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 74 20 our -PRON- PRP$ work_ksthdbpq7vbwdm3jhrt2dav524 74 21 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 74 22 , , , work_ksthdbpq7vbwdm3jhrt2dav524 74 23 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 74 24 although although IN work_ksthdbpq7vbwdm3jhrt2dav524 74 25 this this DT work_ksthdbpq7vbwdm3jhrt2dav524 74 26 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 74 27 showed show VBD work_ksthdbpq7vbwdm3jhrt2dav524 74 28 significant significant JJ work_ksthdbpq7vbwdm3jhrt2dav524 74 29 improvements improvement NNS work_ksthdbpq7vbwdm3jhrt2dav524 74 30 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 74 31 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 74 32 overall overall JJ work_ksthdbpq7vbwdm3jhrt2dav524 74 33 RR RR NNP work_ksthdbpq7vbwdm3jhrt2dav524 74 34 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 74 35 PFS PFS NNP work_ksthdbpq7vbwdm3jhrt2dav524 74 36 , , , work_ksthdbpq7vbwdm3jhrt2dav524 74 37 it -PRON- PRP work_ksthdbpq7vbwdm3jhrt2dav524 74 38 failed fail VBD work_ksthdbpq7vbwdm3jhrt2dav524 74 39 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 74 40 meet meet VB work_ksthdbpq7vbwdm3jhrt2dav524 74 41 its -PRON- PRP$ work_ksthdbpq7vbwdm3jhrt2dav524 74 42 primary primary JJ work_ksthdbpq7vbwdm3jhrt2dav524 74 43 end end NN work_ksthdbpq7vbwdm3jhrt2dav524 74 44 point point NN work_ksthdbpq7vbwdm3jhrt2dav524 74 45 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 74 46 improved improved JJ work_ksthdbpq7vbwdm3jhrt2dav524 74 47 oS oS NNP work_ksthdbpq7vbwdm3jhrt2dav524 74 48 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 74 49 10.1 10.1 CD work_ksthdbpq7vbwdm3jhrt2dav524 74 50 versus versus IN work_ksthdbpq7vbwdm3jhrt2dav524 74 51 12.1 12.1 CD work_ksthdbpq7vbwdm3jhrt2dav524 74 52 months month NNS work_ksthdbpq7vbwdm3jhrt2dav524 74 53 [ [ -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 74 54 p p NN work_ksthdbpq7vbwdm3jhrt2dav524 74 55 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 74 56 0.1]).15 0.1]).15 . work_ksthdbpq7vbwdm3jhrt2dav524 74 57 Sunitinib Sunitinib NNP work_ksthdbpq7vbwdm3jhrt2dav524 74 58 has have VBZ work_ksthdbpq7vbwdm3jhrt2dav524 74 59 been be VBN work_ksthdbpq7vbwdm3jhrt2dav524 74 60 evaluated evaluate VBN work_ksthdbpq7vbwdm3jhrt2dav524 74 61 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 74 62 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 74 63 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 74 64 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 74 65 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 74 66 adjuvant adjuvant JJ work_ksthdbpq7vbwdm3jhrt2dav524 74 67 setting setting NN work_ksthdbpq7vbwdm3jhrt2dav524 74 68 , , , work_ksthdbpq7vbwdm3jhrt2dav524 74 69 looking look VBG work_ksthdbpq7vbwdm3jhrt2dav524 74 70 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 74 71 neoadjuvant neoadjuvant JJ work_ksthdbpq7vbwdm3jhrt2dav524 74 72 irinotecan irinotecan NNP work_ksthdbpq7vbwdm3jhrt2dav524 74 73 + + CC work_ksthdbpq7vbwdm3jhrt2dav524 74 74 cisplatin cisplatin NN work_ksthdbpq7vbwdm3jhrt2dav524 74 75 combined combine VBN work_ksthdbpq7vbwdm3jhrt2dav524 74 76 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 74 77 radiation radiation NN work_ksthdbpq7vbwdm3jhrt2dav524 74 78 followed follow VBN work_ksthdbpq7vbwdm3jhrt2dav524 74 79 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 74 80 esophagectomy esophagectomy NNP work_ksthdbpq7vbwdm3jhrt2dav524 74 81 followed follow VBN work_ksthdbpq7vbwdm3jhrt2dav524 74 82 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 74 83 adjuvant adjuvant JJ work_ksthdbpq7vbwdm3jhrt2dav524 74 84 sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 74 85 therapy therapy NN work_ksthdbpq7vbwdm3jhrt2dav524 74 86 . . . work_ksthdbpq7vbwdm3jhrt2dav524 75 1 In in IN work_ksthdbpq7vbwdm3jhrt2dav524 75 2 this this DT work_ksthdbpq7vbwdm3jhrt2dav524 75 3 phase phase NN work_ksthdbpq7vbwdm3jhrt2dav524 75 4 II ii CD work_ksthdbpq7vbwdm3jhrt2dav524 75 5 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 75 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 75 7 70 70 CD work_ksthdbpq7vbwdm3jhrt2dav524 75 8 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 75 9 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 75 10 enrolled enrol VBN work_ksthdbpq7vbwdm3jhrt2dav524 75 11 ; ; , work_ksthdbpq7vbwdm3jhrt2dav524 75 12 following follow VBG work_ksthdbpq7vbwdm3jhrt2dav524 75 13 esophagectomy esophagectomy NNP work_ksthdbpq7vbwdm3jhrt2dav524 75 14 only only RB work_ksthdbpq7vbwdm3jhrt2dav524 75 15 20 20 CD work_ksthdbpq7vbwdm3jhrt2dav524 75 16 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 75 17 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 75 18 fit fit JJ work_ksthdbpq7vbwdm3jhrt2dav524 75 19 enough enough RB work_ksthdbpq7vbwdm3jhrt2dav524 75 20 to to TO work_ksthdbpq7vbwdm3jhrt2dav524 75 21 receive receive VB work_ksthdbpq7vbwdm3jhrt2dav524 75 22 sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 75 23 therapy therapy NN work_ksthdbpq7vbwdm3jhrt2dav524 75 24 . . . work_ksthdbpq7vbwdm3jhrt2dav524 76 1 Median Median NNP work_ksthdbpq7vbwdm3jhrt2dav524 76 2 oS oS NNP work_ksthdbpq7vbwdm3jhrt2dav524 76 3 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 76 4 this this DT work_ksthdbpq7vbwdm3jhrt2dav524 76 5 locally locally RB work_ksthdbpq7vbwdm3jhrt2dav524 76 6 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 76 7 population population NN work_ksthdbpq7vbwdm3jhrt2dav524 76 8 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 76 9 26 26 CD work_ksthdbpq7vbwdm3jhrt2dav524 76 10 months month NNS work_ksthdbpq7vbwdm3jhrt2dav524 76 11 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 76 12 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 76 13 2-year 2-year CD work_ksthdbpq7vbwdm3jhrt2dav524 76 14 oS os NN work_ksthdbpq7vbwdm3jhrt2dav524 76 15 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 76 16 around around RB work_ksthdbpq7vbwdm3jhrt2dav524 76 17 50 50 CD work_ksthdbpq7vbwdm3jhrt2dav524 76 18 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 76 19 . . . work_ksthdbpq7vbwdm3jhrt2dav524 77 1 Specific specific JJ work_ksthdbpq7vbwdm3jhrt2dav524 77 2 toxicity toxicity NN work_ksthdbpq7vbwdm3jhrt2dav524 77 3 data datum NNS work_ksthdbpq7vbwdm3jhrt2dav524 77 4 are be VBP work_ksthdbpq7vbwdm3jhrt2dav524 77 5 not not RB work_ksthdbpq7vbwdm3jhrt2dav524 77 6 yet yet RB work_ksthdbpq7vbwdm3jhrt2dav524 77 7 available.7 available.7 UH work_ksthdbpq7vbwdm3jhrt2dav524 77 8 Currently currently RB work_ksthdbpq7vbwdm3jhrt2dav524 77 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 77 10 there there EX work_ksthdbpq7vbwdm3jhrt2dav524 77 11 is be VBZ work_ksthdbpq7vbwdm3jhrt2dav524 77 12 an an DT work_ksthdbpq7vbwdm3jhrt2dav524 77 13 ongoing ongoing JJ work_ksthdbpq7vbwdm3jhrt2dav524 77 14 phase phase NN work_ksthdbpq7vbwdm3jhrt2dav524 77 15 II ii CD work_ksthdbpq7vbwdm3jhrt2dav524 77 16 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 77 17 comparing compare VBG work_ksthdbpq7vbwdm3jhrt2dav524 77 18 suni- suni- NNP work_ksthdbpq7vbwdm3jhrt2dav524 77 19 tinib tinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 77 20 single single JJ work_ksthdbpq7vbwdm3jhrt2dav524 77 21 agent agent NN work_ksthdbpq7vbwdm3jhrt2dav524 77 22 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 77 23 placebo placebo NN work_ksthdbpq7vbwdm3jhrt2dav524 77 24 therapy therapy NN work_ksthdbpq7vbwdm3jhrt2dav524 77 25 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 77 26 relapsed relapsed JJ work_ksthdbpq7vbwdm3jhrt2dav524 77 27 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 77 28 refractory refractory NN work_ksthdbpq7vbwdm3jhrt2dav524 77 29 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 77 30 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 77 31 GE GE NNP work_ksthdbpq7vbwdm3jhrt2dav524 77 32 junction junction NN work_ksthdbpq7vbwdm3jhrt2dav524 77 33 carcinoma carcinoma NN work_ksthdbpq7vbwdm3jhrt2dav524 77 34 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 77 35 ClincalTrials.gov ClincalTrials.gov NNP work_ksthdbpq7vbwdm3jhrt2dav524 77 36 ID ID NNP work_ksthdbpq7vbwdm3jhrt2dav524 77 37 # # NNP work_ksthdbpq7vbwdm3jhrt2dav524 77 38 NCT00702884 NCT00702884 NNP work_ksthdbpq7vbwdm3jhrt2dav524 77 39 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 77 40 . . . work_ksthdbpq7vbwdm3jhrt2dav524 78 1 The the DT work_ksthdbpq7vbwdm3jhrt2dav524 78 2 sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 78 3 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 78 4 specific specific JJ work_ksthdbpq7vbwdm3jhrt2dav524 78 5 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 78 6 observed observe VBN work_ksthdbpq7vbwdm3jhrt2dav524 78 7 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 78 8 our -PRON- PRP$ work_ksthdbpq7vbwdm3jhrt2dav524 78 9 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 78 10 were be VBD work_ksthdbpq7vbwdm3jhrt2dav524 78 11 similar similar JJ work_ksthdbpq7vbwdm3jhrt2dav524 78 12 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 78 13 those those DT work_ksthdbpq7vbwdm3jhrt2dav524 78 14 previously previously RB work_ksthdbpq7vbwdm3jhrt2dav524 78 15 reported report VBN work_ksthdbpq7vbwdm3jhrt2dav524 78 16 ; ; : work_ksthdbpq7vbwdm3jhrt2dav524 78 17 however however RB work_ksthdbpq7vbwdm3jhrt2dav524 78 18 , , , work_ksthdbpq7vbwdm3jhrt2dav524 78 19 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 78 20 increased increase VBN work_ksthdbpq7vbwdm3jhrt2dav524 78 21 incidence incidence NN work_ksthdbpq7vbwdm3jhrt2dav524 78 22 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 78 23 grade grade NN work_ksthdbpq7vbwdm3jhrt2dav524 78 24 3/4/5 3/4/5 CD work_ksthdbpq7vbwdm3jhrt2dav524 78 25 hemorrhage hemorrhage NN work_ksthdbpq7vbwdm3jhrt2dav524 78 26 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 78 27 con- con- NN work_ksthdbpq7vbwdm3jhrt2dav524 78 28 cerning cerne VBG work_ksthdbpq7vbwdm3jhrt2dav524 78 29 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 78 30 this this DT work_ksthdbpq7vbwdm3jhrt2dav524 78 31 combination combination NN work_ksthdbpq7vbwdm3jhrt2dav524 78 32 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 78 33 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 78 34 not not RB work_ksthdbpq7vbwdm3jhrt2dav524 78 35 previously previously RB work_ksthdbpq7vbwdm3jhrt2dav524 78 36 reported report VBN work_ksthdbpq7vbwdm3jhrt2dav524 78 37 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 78 38 therapy therapy NN work_ksthdbpq7vbwdm3jhrt2dav524 78 39 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 78 40 taxanes taxane NNS work_ksthdbpq7vbwdm3jhrt2dav524 78 41 alone alone JJ work_ksthdbpq7vbwdm3jhrt2dav524 78 42 , , , work_ksthdbpq7vbwdm3jhrt2dav524 78 43 combination combination NN work_ksthdbpq7vbwdm3jhrt2dav524 78 44 regimens regimen VBZ work_ksthdbpq7vbwdm3jhrt2dav524 78 45 contain- contain- NNP work_ksthdbpq7vbwdm3jhrt2dav524 78 46 ing ing NNP work_ksthdbpq7vbwdm3jhrt2dav524 78 47 taxanes taxane NNS work_ksthdbpq7vbwdm3jhrt2dav524 78 48 , , , work_ksthdbpq7vbwdm3jhrt2dav524 78 49 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 78 50 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 78 51 other other JJ work_ksthdbpq7vbwdm3jhrt2dav524 78 52 VEGF vegf NN work_ksthdbpq7vbwdm3jhrt2dav524 78 53 inhibitors inhibitor NNS work_ksthdbpq7vbwdm3jhrt2dav524 78 54 . . . work_ksthdbpq7vbwdm3jhrt2dav524 79 1 In in IN work_ksthdbpq7vbwdm3jhrt2dav524 79 2 conclusion conclusion NN work_ksthdbpq7vbwdm3jhrt2dav524 79 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 79 4 our -PRON- PRP$ work_ksthdbpq7vbwdm3jhrt2dav524 79 5 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 79 6 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 79 7 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 79 8 combination combination NN work_ksthdbpq7vbwdm3jhrt2dav524 79 9 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 79 10 sunitinib sunitinib NNP work_ksthdbpq7vbwdm3jhrt2dav524 79 11 + + SYM work_ksthdbpq7vbwdm3jhrt2dav524 79 12 paclitaxel paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 79 13 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 79 14 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 79 15 esophageal esophageal NN work_ksthdbpq7vbwdm3jhrt2dav524 79 16 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 79 17 GE GE NNP work_ksthdbpq7vbwdm3jhrt2dav524 79 18 junction junction NN work_ksthdbpq7vbwdm3jhrt2dav524 79 19 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 79 20 was be VBD work_ksthdbpq7vbwdm3jhrt2dav524 79 21 negative negative JJ work_ksthdbpq7vbwdm3jhrt2dav524 79 22 as as IN work_ksthdbpq7vbwdm3jhrt2dav524 79 23 it -PRON- PRP work_ksthdbpq7vbwdm3jhrt2dav524 79 24 did do VBD work_ksthdbpq7vbwdm3jhrt2dav524 79 25 not not RB work_ksthdbpq7vbwdm3jhrt2dav524 79 26 meet meet VB work_ksthdbpq7vbwdm3jhrt2dav524 79 27 our -PRON- PRP$ work_ksthdbpq7vbwdm3jhrt2dav524 79 28 primary primary JJ work_ksthdbpq7vbwdm3jhrt2dav524 79 29 end end NN work_ksthdbpq7vbwdm3jhrt2dav524 79 30 point point NN work_ksthdbpq7vbwdm3jhrt2dav524 79 31 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 79 32 50 50 CD work_ksthdbpq7vbwdm3jhrt2dav524 79 33 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 79 34 PFS PFS NNP work_ksthdbpq7vbwdm3jhrt2dav524 79 35 at at IN work_ksthdbpq7vbwdm3jhrt2dav524 79 36 24 24 CD work_ksthdbpq7vbwdm3jhrt2dav524 79 37 weeks week NNS work_ksthdbpq7vbwdm3jhrt2dav524 79 38 , , , work_ksthdbpq7vbwdm3jhrt2dav524 79 39 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 79 40 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 79 41 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 79 42 high high JJ work_ksthdbpq7vbwdm3jhrt2dav524 79 43 rate rate NN work_ksthdbpq7vbwdm3jhrt2dav524 79 44 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 79 45 serious serious JJ work_ksthdbpq7vbwdm3jhrt2dav524 79 46 toxicities toxicity NNS work_ksthdbpq7vbwdm3jhrt2dav524 79 47 , , , work_ksthdbpq7vbwdm3jhrt2dav524 79 48 including include VBG work_ksthdbpq7vbwdm3jhrt2dav524 79 49 four four CD work_ksthdbpq7vbwdm3jhrt2dav524 79 50 grade-5 grade-5 NNP work_ksthdbpq7vbwdm3jhrt2dav524 79 51 events event NNS work_ksthdbpq7vbwdm3jhrt2dav524 79 52 , , , work_ksthdbpq7vbwdm3jhrt2dav524 79 53 this this DT work_ksthdbpq7vbwdm3jhrt2dav524 79 54 combination combination NN work_ksthdbpq7vbwdm3jhrt2dav524 79 55 will will MD work_ksthdbpq7vbwdm3jhrt2dav524 79 56 not not RB work_ksthdbpq7vbwdm3jhrt2dav524 79 57 be be VB work_ksthdbpq7vbwdm3jhrt2dav524 79 58 pursued pursue VBN work_ksthdbpq7vbwdm3jhrt2dav524 79 59 further further RB work_ksthdbpq7vbwdm3jhrt2dav524 79 60 . . . work_ksthdbpq7vbwdm3jhrt2dav524 80 1 REFERENCES reference NNS work_ksthdbpq7vbwdm3jhrt2dav524 80 2 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 80 3 . . . work_ksthdbpq7vbwdm3jhrt2dav524 81 1 Jemal Jemal NNP work_ksthdbpq7vbwdm3jhrt2dav524 81 2 A A NNP work_ksthdbpq7vbwdm3jhrt2dav524 81 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 81 4 Siegel Siegel NNP work_ksthdbpq7vbwdm3jhrt2dav524 81 5 R R NNP work_ksthdbpq7vbwdm3jhrt2dav524 81 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 81 7 Xu Xu NNP work_ksthdbpq7vbwdm3jhrt2dav524 81 8 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 81 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 81 10 Ward Ward NNP work_ksthdbpq7vbwdm3jhrt2dav524 81 11 E. E. NNP work_ksthdbpq7vbwdm3jhrt2dav524 81 12 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 81 13 statistics statistic NNS work_ksthdbpq7vbwdm3jhrt2dav524 81 14 , , , work_ksthdbpq7vbwdm3jhrt2dav524 81 15 2010 2010 CD work_ksthdbpq7vbwdm3jhrt2dav524 81 16 . . . work_ksthdbpq7vbwdm3jhrt2dav524 82 1 CA CA NNP work_ksthdbpq7vbwdm3jhrt2dav524 82 2 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 82 3 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 82 4 Clin Clin NNP work_ksthdbpq7vbwdm3jhrt2dav524 82 5 2010;60:277–300 2010;60:277–300 CD work_ksthdbpq7vbwdm3jhrt2dav524 82 6 . . . work_ksthdbpq7vbwdm3jhrt2dav524 83 1 2 2 LS work_ksthdbpq7vbwdm3jhrt2dav524 83 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 84 1 Shah Shah NNP work_ksthdbpq7vbwdm3jhrt2dav524 84 2 MA MA NNP work_ksthdbpq7vbwdm3jhrt2dav524 84 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 84 4 Schwartz Schwartz NNP work_ksthdbpq7vbwdm3jhrt2dav524 84 5 GK GK NNP work_ksthdbpq7vbwdm3jhrt2dav524 84 6 . . . work_ksthdbpq7vbwdm3jhrt2dav524 85 1 Treatment treatment NN work_ksthdbpq7vbwdm3jhrt2dav524 85 2 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 85 3 metastatic metastatic JJ work_ksthdbpq7vbwdm3jhrt2dav524 85 4 esophagus esophagus NN work_ksthdbpq7vbwdm3jhrt2dav524 85 5 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 85 6 gastric gastric JJ work_ksthdbpq7vbwdm3jhrt2dav524 85 7 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 85 8 . . . work_ksthdbpq7vbwdm3jhrt2dav524 86 1 Semin Semin NNP work_ksthdbpq7vbwdm3jhrt2dav524 86 2 Oncol Oncol NNP work_ksthdbpq7vbwdm3jhrt2dav524 86 3 2004;31:574–587 2004;31:574–587 NNP work_ksthdbpq7vbwdm3jhrt2dav524 86 4 . . . work_ksthdbpq7vbwdm3jhrt2dav524 87 1 TABLE TABLE NNP work_ksthdbpq7vbwdm3jhrt2dav524 87 2 3 3 CD work_ksthdbpq7vbwdm3jhrt2dav524 87 3 . . . work_ksthdbpq7vbwdm3jhrt2dav524 88 1 Selected Selected NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 2 Nonhematologic Nonhematologic NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 3 Toxicities Toxicities NNPS work_ksthdbpq7vbwdm3jhrt2dav524 88 4 Irrespective Irrespective NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 5 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 88 6 Causality Causality NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 7 Attributed attribute VBN work_ksthdbpq7vbwdm3jhrt2dav524 88 8 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 88 9 n n CC work_ksthdbpq7vbwdm3jhrt2dav524 88 10 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 11 28 28 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 12 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 88 13 Grade Grade NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 14 3 3 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 15 Grade Grade NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 16 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 17 Grade Grade NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 18 3/4 3/4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 19 Grade Grade NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 20 5 5 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 21 Hemorrhage Hemorrhage NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 22 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 23 bleeding bleed VBG work_ksthdbpq7vbwdm3jhrt2dav524 88 24 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 25 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 26 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 27 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 28 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 29 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 30 3 3 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 31 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 32 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 33 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 34 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 35 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 36 Thrombosis Thrombosis NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 37 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 38 thrombus thrombus NN work_ksthdbpq7vbwdm3jhrt2dav524 88 39 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 40 embolism embolism NN work_ksthdbpq7vbwdm3jhrt2dav524 88 41 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 42 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 43 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 44 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 45 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 46 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 47 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 48 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 49 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 50 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 51 Fistula Fistula NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 52 , , , work_ksthdbpq7vbwdm3jhrt2dav524 88 53 GI GI NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 54 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 55 esophagus esophagus NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 56 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 57 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 58 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 59 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 60 — — SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 61 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 62 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 63 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 64 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 65 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 66 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 67 Rash Rash NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 68 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 69 dermatologic dermatologic JJ work_ksthdbpq7vbwdm3jhrt2dav524 88 70 complaints complaint NNS work_ksthdbpq7vbwdm3jhrt2dav524 88 71 0 0 NFP work_ksthdbpq7vbwdm3jhrt2dav524 88 72 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 73 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 74 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 75 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 76 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 77 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 78 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 79 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 80 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 81 Dyspnea Dyspnea NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 82 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 83 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 84 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 85 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 86 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 87 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 88 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 89 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 90 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 91 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 92 Neuropathy neuropathy NN work_ksthdbpq7vbwdm3jhrt2dav524 88 93 : : : work_ksthdbpq7vbwdm3jhrt2dav524 88 94 motor motor NN work_ksthdbpq7vbwdm3jhrt2dav524 88 95 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 96 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 97 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 98 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 99 — — SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 100 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 101 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 102 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 103 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 104 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 105 Allergic allergic JJ work_ksthdbpq7vbwdm3jhrt2dav524 88 106 reaction reaction NN work_ksthdbpq7vbwdm3jhrt2dav524 88 107 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 108 hypersensitivity hypersensitivity NN work_ksthdbpq7vbwdm3jhrt2dav524 88 109 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 88 110 including include VBG work_ksthdbpq7vbwdm3jhrt2dav524 88 111 drug drug NN work_ksthdbpq7vbwdm3jhrt2dav524 88 112 fever fever NN work_ksthdbpq7vbwdm3jhrt2dav524 88 113 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 88 114 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 115 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 116 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 117 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 118 — — SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 119 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 120 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 121 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 122 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 123 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 124 Pulmonary Pulmonary NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 125 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 88 126 effusion effusion NN work_ksthdbpq7vbwdm3jhrt2dav524 88 127 , , , work_ksthdbpq7vbwdm3jhrt2dav524 88 128 pneumonitis pneumonitis NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 129 NoS NoS NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 130 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 88 131 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 132 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 133 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 134 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 135 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 136 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 137 3 3 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 138 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 139 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 140 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 141 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 142 Fatigue Fatigue NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 143 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 88 144 asthenia asthenia NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 145 , , , work_ksthdbpq7vbwdm3jhrt2dav524 88 146 lethargy lethargy NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 147 , , , work_ksthdbpq7vbwdm3jhrt2dav524 88 148 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 88 149 malaise malaise NN work_ksthdbpq7vbwdm3jhrt2dav524 88 150 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 88 151 3 3 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 152 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 153 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 154 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 155 — — SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 156 3 3 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 157 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 158 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 159 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 160 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 161 Diarrhea diarrhea NN work_ksthdbpq7vbwdm3jhrt2dav524 88 162 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 163 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 164 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 165 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 166 — — SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 167 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 168 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 169 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 170 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 171 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 172 Dysphagia Dysphagia NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 173 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 174 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 175 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 176 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 177 — — SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 178 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 179 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 180 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 181 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 182 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 183 Hyponatremia hyponatremia NN work_ksthdbpq7vbwdm3jhrt2dav524 88 184 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 185 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 186 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 187 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 188 — — SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 189 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 190 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 191 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 192 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 193 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 194 Hyperglycemia hyperglycemia NN work_ksthdbpq7vbwdm3jhrt2dav524 88 195 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 196 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 197 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 198 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 199 — — SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 200 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 201 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 202 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 203 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 204 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 205 Death death NN work_ksthdbpq7vbwdm3jhrt2dav524 88 206 NoS nos NN work_ksthdbpq7vbwdm3jhrt2dav524 88 207 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 208 — — : work_ksthdbpq7vbwdm3jhrt2dav524 88 209 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 210 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 211 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 212 0 0 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 213 — — SYM work_ksthdbpq7vbwdm3jhrt2dav524 88 214 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 215 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 88 216 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 88 217 GI GI NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 218 , , , work_ksthdbpq7vbwdm3jhrt2dav524 88 219 gastrointestinal gastrointestinal JJ work_ksthdbpq7vbwdm3jhrt2dav524 88 220 ; ; : work_ksthdbpq7vbwdm3jhrt2dav524 88 221 NoS NoS NNP work_ksthdbpq7vbwdm3jhrt2dav524 88 222 , , , work_ksthdbpq7vbwdm3jhrt2dav524 88 223 not not RB work_ksthdbpq7vbwdm3jhrt2dav524 88 224 otherwise otherwise RB work_ksthdbpq7vbwdm3jhrt2dav524 88 225 specified specify VBN work_ksthdbpq7vbwdm3jhrt2dav524 88 226 . . . work_ksthdbpq7vbwdm3jhrt2dav524 89 1 TABLE TABLE NNP work_ksthdbpq7vbwdm3jhrt2dav524 89 2 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 89 3 . . . work_ksthdbpq7vbwdm3jhrt2dav524 90 1 Grade Grade NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 2 5 5 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 3 Toxicity Toxicity NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 4 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 90 5 Treatment Treatment NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 6 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 90 7 Related Related NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 8 Death Death NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 9 Evaluable Evaluable NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 10 Population Population NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 11 ( ( -LRB- work_ksthdbpq7vbwdm3jhrt2dav524 90 12 n n NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 13 = = SYM work_ksthdbpq7vbwdm3jhrt2dav524 90 14 23 23 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 15 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 90 16 N n CD work_ksthdbpq7vbwdm3jhrt2dav524 90 17 % % NN work_ksthdbpq7vbwdm3jhrt2dav524 90 18 Cycle Cycle NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 19 Consequence Consequence NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 20 Attribution Attribution NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 21 Hemorrhage Hemorrhage NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 22 , , , work_ksthdbpq7vbwdm3jhrt2dav524 90 23 GI/ gi/ DT work_ksthdbpq7vbwdm3jhrt2dav524 90 24 upper upper JJ work_ksthdbpq7vbwdm3jhrt2dav524 90 25 GI GI NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 26 NoS NoS NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 27 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 28 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 29 Maintenance Maintenance NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 30 Death Death NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 31 Possible Possible NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 32 Fistula Fistula NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 33 , , , work_ksthdbpq7vbwdm3jhrt2dav524 90 34 GI/ gi/ DT work_ksthdbpq7vbwdm3jhrt2dav524 90 35 esophagus esophagus NN work_ksthdbpq7vbwdm3jhrt2dav524 90 36 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 37 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 38 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 39 Death Death NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 40 Unrelated Unrelated NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 41 Death Death NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 42 NoS nos NN work_ksthdbpq7vbwdm3jhrt2dav524 90 43 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 44 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 45 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 46 Death death NN work_ksthdbpq7vbwdm3jhrt2dav524 90 47 Probably probably RB work_ksthdbpq7vbwdm3jhrt2dav524 90 48 Hemorrhage Hemorrhage NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 49 , , , work_ksthdbpq7vbwdm3jhrt2dav524 90 50 GI/ gi/ DT work_ksthdbpq7vbwdm3jhrt2dav524 90 51 stomach stomach NN work_ksthdbpq7vbwdm3jhrt2dav524 90 52 1 1 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 53 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 54 2 2 CD work_ksthdbpq7vbwdm3jhrt2dav524 90 55 Death death NN work_ksthdbpq7vbwdm3jhrt2dav524 90 56 Possible possible JJ work_ksthdbpq7vbwdm3jhrt2dav524 90 57 GI GI NNP work_ksthdbpq7vbwdm3jhrt2dav524 90 58 , , , work_ksthdbpq7vbwdm3jhrt2dav524 90 59 gastrointestinal gastrointestinal JJ work_ksthdbpq7vbwdm3jhrt2dav524 90 60 . . . work_ksthdbpq7vbwdm3jhrt2dav524 91 1 763Copyright 763copyright CD work_ksthdbpq7vbwdm3jhrt2dav524 91 2 © © NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 3 2012 2012 CD work_ksthdbpq7vbwdm3jhrt2dav524 91 4 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 91 5 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 91 6 International International NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 7 Association Association NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 8 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 91 9 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 91 10 Study Study NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 11 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 91 12 Lung Lung NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 13 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 14 Journal Journal NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 15 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 91 16 Thoracic Thoracic NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 17 Oncology Oncology NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 18 • • NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 19 Volume volume NN work_ksthdbpq7vbwdm3jhrt2dav524 91 20 7 7 CD work_ksthdbpq7vbwdm3jhrt2dav524 91 21 , , , work_ksthdbpq7vbwdm3jhrt2dav524 91 22 Number number NN work_ksthdbpq7vbwdm3jhrt2dav524 91 23 4 4 CD work_ksthdbpq7vbwdm3jhrt2dav524 91 24 , , , work_ksthdbpq7vbwdm3jhrt2dav524 91 25 April April NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 26 2012 2012 CD work_ksthdbpq7vbwdm3jhrt2dav524 91 27 Sunitinib Sunitinib NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 28 Plus Plus NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 29 Paclitaxel Paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 30 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 91 31 Esophageal Esophageal NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 32 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 91 33 Patients Patients NNPS work_ksthdbpq7vbwdm3jhrt2dav524 91 34 3 3 CD work_ksthdbpq7vbwdm3jhrt2dav524 91 35 . . . work_ksthdbpq7vbwdm3jhrt2dav524 92 1 Cunningham Cunningham NNP work_ksthdbpq7vbwdm3jhrt2dav524 92 2 D D NNP work_ksthdbpq7vbwdm3jhrt2dav524 92 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 92 4 Starling Starling NNP work_ksthdbpq7vbwdm3jhrt2dav524 92 5 N N NNP work_ksthdbpq7vbwdm3jhrt2dav524 92 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 92 7 Rao Rao NNP work_ksthdbpq7vbwdm3jhrt2dav524 92 8 S S NNP work_ksthdbpq7vbwdm3jhrt2dav524 92 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 92 10 et et NNP work_ksthdbpq7vbwdm3jhrt2dav524 92 11 al al NNP work_ksthdbpq7vbwdm3jhrt2dav524 92 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 93 1 ; ; : work_ksthdbpq7vbwdm3jhrt2dav524 93 2 Upper Upper NNP work_ksthdbpq7vbwdm3jhrt2dav524 93 3 Gastrointestinal Gastrointestinal NNP work_ksthdbpq7vbwdm3jhrt2dav524 93 4 Clinical Clinical NNP work_ksthdbpq7vbwdm3jhrt2dav524 93 5 Studies Studies NNPS work_ksthdbpq7vbwdm3jhrt2dav524 93 6 Group Group NNP work_ksthdbpq7vbwdm3jhrt2dav524 93 7 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 93 8 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 93 9 National National NNP work_ksthdbpq7vbwdm3jhrt2dav524 93 10 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 93 11 Research Research NNP work_ksthdbpq7vbwdm3jhrt2dav524 93 12 Institute Institute NNP work_ksthdbpq7vbwdm3jhrt2dav524 93 13 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 93 14 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 93 15 United United NNP work_ksthdbpq7vbwdm3jhrt2dav524 93 16 Kingdom Kingdom NNP work_ksthdbpq7vbwdm3jhrt2dav524 93 17 . . . work_ksthdbpq7vbwdm3jhrt2dav524 94 1 Capecitabine Capecitabine NNP work_ksthdbpq7vbwdm3jhrt2dav524 94 2 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 94 3 oxaliplatin oxaliplatin NN work_ksthdbpq7vbwdm3jhrt2dav524 94 4 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 94 5 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 94 6 esophagogastric esophagogastric JJ work_ksthdbpq7vbwdm3jhrt2dav524 94 7 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 94 8 . . . work_ksthdbpq7vbwdm3jhrt2dav524 95 1 N N NNP work_ksthdbpq7vbwdm3jhrt2dav524 95 2 Engl Engl NNP work_ksthdbpq7vbwdm3jhrt2dav524 95 3 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 95 4 Med Med NNP work_ksthdbpq7vbwdm3jhrt2dav524 95 5 2008;358:36–46 2008;358:36–46 CD work_ksthdbpq7vbwdm3jhrt2dav524 95 6 . . . work_ksthdbpq7vbwdm3jhrt2dav524 96 1 4 4 LS work_ksthdbpq7vbwdm3jhrt2dav524 96 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 97 1 Kleespies Kleespies NNPS work_ksthdbpq7vbwdm3jhrt2dav524 97 2 A A NNP work_ksthdbpq7vbwdm3jhrt2dav524 97 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 97 4 Guba Guba NNP work_ksthdbpq7vbwdm3jhrt2dav524 97 5 M M NNP work_ksthdbpq7vbwdm3jhrt2dav524 97 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 97 7 Jauch Jauch NNP work_ksthdbpq7vbwdm3jhrt2dav524 97 8 KW KW NNP work_ksthdbpq7vbwdm3jhrt2dav524 97 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 97 10 Bruns Bruns NNP work_ksthdbpq7vbwdm3jhrt2dav524 97 11 CJ CJ NNP work_ksthdbpq7vbwdm3jhrt2dav524 97 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 98 1 Vascular vascular JJ work_ksthdbpq7vbwdm3jhrt2dav524 98 2 endothelial endothelial JJ work_ksthdbpq7vbwdm3jhrt2dav524 98 3 growth growth NN work_ksthdbpq7vbwdm3jhrt2dav524 98 4 factor factor NN work_ksthdbpq7vbwdm3jhrt2dav524 98 5 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 98 6 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 98 7 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 98 8 . . . work_ksthdbpq7vbwdm3jhrt2dav524 99 1 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 99 2 Surg Surg NNP work_ksthdbpq7vbwdm3jhrt2dav524 99 3 Oncol Oncol NNP work_ksthdbpq7vbwdm3jhrt2dav524 99 4 2004;87:95–104 2004;87:95–104 CD work_ksthdbpq7vbwdm3jhrt2dav524 99 5 . . . work_ksthdbpq7vbwdm3jhrt2dav524 100 1 5 5 CD work_ksthdbpq7vbwdm3jhrt2dav524 100 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 101 1 Chow Chow NNP work_ksthdbpq7vbwdm3jhrt2dav524 101 2 LQ LQ NNP work_ksthdbpq7vbwdm3jhrt2dav524 101 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 101 4 Eckhardt Eckhardt NNP work_ksthdbpq7vbwdm3jhrt2dav524 101 5 SG SG NNP work_ksthdbpq7vbwdm3jhrt2dav524 101 6 . . . work_ksthdbpq7vbwdm3jhrt2dav524 102 1 Sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 102 2 : : : work_ksthdbpq7vbwdm3jhrt2dav524 102 3 from from IN work_ksthdbpq7vbwdm3jhrt2dav524 102 4 rational rational JJ work_ksthdbpq7vbwdm3jhrt2dav524 102 5 design design NN work_ksthdbpq7vbwdm3jhrt2dav524 102 6 to to IN work_ksthdbpq7vbwdm3jhrt2dav524 102 7 clinical clinical JJ work_ksthdbpq7vbwdm3jhrt2dav524 102 8 efficacy efficacy NN work_ksthdbpq7vbwdm3jhrt2dav524 102 9 . . . work_ksthdbpq7vbwdm3jhrt2dav524 103 1 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 103 2 Clin Clin NNP work_ksthdbpq7vbwdm3jhrt2dav524 103 3 Oncol Oncol NNP work_ksthdbpq7vbwdm3jhrt2dav524 103 4 2007;25:884–896 2007;25:884–896 CD work_ksthdbpq7vbwdm3jhrt2dav524 103 5 . . . work_ksthdbpq7vbwdm3jhrt2dav524 104 1 6 6 LS work_ksthdbpq7vbwdm3jhrt2dav524 104 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 104 3 orestis orestis NNP work_ksthdbpq7vbwdm3jhrt2dav524 104 4 L L NNP work_ksthdbpq7vbwdm3jhrt2dav524 104 5 , , , work_ksthdbpq7vbwdm3jhrt2dav524 104 6 Annett Annett NNP work_ksthdbpq7vbwdm3jhrt2dav524 104 7 M M NNP work_ksthdbpq7vbwdm3jhrt2dav524 104 8 , , , work_ksthdbpq7vbwdm3jhrt2dav524 104 9 Florian Florian NNP work_ksthdbpq7vbwdm3jhrt2dav524 104 10 H H NNP work_ksthdbpq7vbwdm3jhrt2dav524 104 11 , , , work_ksthdbpq7vbwdm3jhrt2dav524 104 12 et et NNP work_ksthdbpq7vbwdm3jhrt2dav524 104 13 al al NNP work_ksthdbpq7vbwdm3jhrt2dav524 104 14 . . . work_ksthdbpq7vbwdm3jhrt2dav524 105 1 Analysis analysis NN work_ksthdbpq7vbwdm3jhrt2dav524 105 2 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 105 3 anti anti JJ work_ksthdbpq7vbwdm3jhrt2dav524 105 4 - - JJ work_ksthdbpq7vbwdm3jhrt2dav524 105 5 proliferative proliferative JJ work_ksthdbpq7vbwdm3jhrt2dav524 105 6 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 105 7 chemosensitizing chemosensitizing JJ work_ksthdbpq7vbwdm3jhrt2dav524 105 8 effects effect NNS work_ksthdbpq7vbwdm3jhrt2dav524 105 9 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 105 10 sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 105 11 on on IN work_ksthdbpq7vbwdm3jhrt2dav524 105 12 human human JJ work_ksthdbpq7vbwdm3jhrt2dav524 105 13 esophagogastric esophagogastric JJ work_ksthdbpq7vbwdm3jhrt2dav524 105 14 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 105 15 cells cell NNS work_ksthdbpq7vbwdm3jhrt2dav524 105 16 : : : work_ksthdbpq7vbwdm3jhrt2dav524 105 17 synergistic synergistic JJ work_ksthdbpq7vbwdm3jhrt2dav524 105 18 interaction interaction NN work_ksthdbpq7vbwdm3jhrt2dav524 105 19 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 105 20 vandetanib vandetanib NN work_ksthdbpq7vbwdm3jhrt2dav524 105 21 via via IN work_ksthdbpq7vbwdm3jhrt2dav524 105 22 inhibition inhibition NN work_ksthdbpq7vbwdm3jhrt2dav524 105 23 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 105 24 multi multi JJ work_ksthdbpq7vbwdm3jhrt2dav524 105 25 - - JJ work_ksthdbpq7vbwdm3jhrt2dav524 105 26 receptor receptor JJ work_ksthdbpq7vbwdm3jhrt2dav524 105 27 tyrosine tyrosine NN work_ksthdbpq7vbwdm3jhrt2dav524 105 28 kinase kinase NN work_ksthdbpq7vbwdm3jhrt2dav524 105 29 pathways pathway NNS work_ksthdbpq7vbwdm3jhrt2dav524 105 30 . . . work_ksthdbpq7vbwdm3jhrt2dav524 106 1 Int Int NNP work_ksthdbpq7vbwdm3jhrt2dav524 106 2 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 106 3 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 106 4 2010;127:1197 2010;127:1197 CD work_ksthdbpq7vbwdm3jhrt2dav524 106 5 – – : work_ksthdbpq7vbwdm3jhrt2dav524 106 6 1208 1208 CD work_ksthdbpq7vbwdm3jhrt2dav524 106 7 . . . work_ksthdbpq7vbwdm3jhrt2dav524 107 1 7 7 LS work_ksthdbpq7vbwdm3jhrt2dav524 107 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 108 1 Knox Knox NNP work_ksthdbpq7vbwdm3jhrt2dav524 108 2 JJ JJ NNP work_ksthdbpq7vbwdm3jhrt2dav524 108 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 108 4 Wong Wong NNP work_ksthdbpq7vbwdm3jhrt2dav524 108 5 R R NNP work_ksthdbpq7vbwdm3jhrt2dav524 108 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 108 7 Darling Darling NNP work_ksthdbpq7vbwdm3jhrt2dav524 108 8 GE GE NNP work_ksthdbpq7vbwdm3jhrt2dav524 108 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 108 10 et et NNP work_ksthdbpq7vbwdm3jhrt2dav524 108 11 al al NNP work_ksthdbpq7vbwdm3jhrt2dav524 108 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 109 1 Adjuvant adjuvant JJ work_ksthdbpq7vbwdm3jhrt2dav524 109 2 sunitinib sunitinib NN work_ksthdbpq7vbwdm3jhrt2dav524 109 3 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 109 4 locally locally RB work_ksthdbpq7vbwdm3jhrt2dav524 109 5 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 109 6 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 109 7 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 109 8 : : : work_ksthdbpq7vbwdm3jhrt2dav524 109 9 results result NNS work_ksthdbpq7vbwdm3jhrt2dav524 109 10 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 109 11 aphase aphase NN work_ksthdbpq7vbwdm3jhrt2dav524 109 12 II II NNP work_ksthdbpq7vbwdm3jhrt2dav524 109 13 trial trial NN work_ksthdbpq7vbwdm3jhrt2dav524 109 14 . . . work_ksthdbpq7vbwdm3jhrt2dav524 110 1 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 110 2 Clin Clin NNP work_ksthdbpq7vbwdm3jhrt2dav524 110 3 Oncol Oncol NNP work_ksthdbpq7vbwdm3jhrt2dav524 110 4 2011;29(Suppl 2011;29(suppl CD work_ksthdbpq7vbwdm3jhrt2dav524 110 5 ) ) -RRB- work_ksthdbpq7vbwdm3jhrt2dav524 110 6 . . . work_ksthdbpq7vbwdm3jhrt2dav524 111 1 8 8 LS work_ksthdbpq7vbwdm3jhrt2dav524 111 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 112 1 George George NNP work_ksthdbpq7vbwdm3jhrt2dav524 112 2 S S NNP work_ksthdbpq7vbwdm3jhrt2dav524 112 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 112 4 Blay Blay NNP work_ksthdbpq7vbwdm3jhrt2dav524 112 5 JY JY NNP work_ksthdbpq7vbwdm3jhrt2dav524 112 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 112 7 Casali Casali NNP work_ksthdbpq7vbwdm3jhrt2dav524 112 8 PG PG NNP work_ksthdbpq7vbwdm3jhrt2dav524 112 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 112 10 et et NNP work_ksthdbpq7vbwdm3jhrt2dav524 112 11 al al NNP work_ksthdbpq7vbwdm3jhrt2dav524 112 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 113 1 Clinical clinical JJ work_ksthdbpq7vbwdm3jhrt2dav524 113 2 evaluation evaluation NN work_ksthdbpq7vbwdm3jhrt2dav524 113 3 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 113 4 continuous continuous JJ work_ksthdbpq7vbwdm3jhrt2dav524 113 5 daily daily JJ work_ksthdbpq7vbwdm3jhrt2dav524 113 6 dosing dosing NN work_ksthdbpq7vbwdm3jhrt2dav524 113 7 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 113 8 sunitinib sunitinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 113 9 malate malate NN work_ksthdbpq7vbwdm3jhrt2dav524 113 10 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 113 11 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 113 12 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 113 13 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 113 14 gastrointestinal gastrointestinal JJ work_ksthdbpq7vbwdm3jhrt2dav524 113 15 stromal stromal NN work_ksthdbpq7vbwdm3jhrt2dav524 113 16 tumour tumour NN work_ksthdbpq7vbwdm3jhrt2dav524 113 17 after after IN work_ksthdbpq7vbwdm3jhrt2dav524 113 18 imatinib imatinib JJ work_ksthdbpq7vbwdm3jhrt2dav524 113 19 failure failure NN work_ksthdbpq7vbwdm3jhrt2dav524 113 20 . . . work_ksthdbpq7vbwdm3jhrt2dav524 114 1 Eur Eur NNP work_ksthdbpq7vbwdm3jhrt2dav524 114 2 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 114 3 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 114 4 2009;45:1959 2009;45:1959 CD work_ksthdbpq7vbwdm3jhrt2dav524 114 5 – – : work_ksthdbpq7vbwdm3jhrt2dav524 114 6 1968 1968 CD work_ksthdbpq7vbwdm3jhrt2dav524 114 7 . . . work_ksthdbpq7vbwdm3jhrt2dav524 115 1 9 9 CD work_ksthdbpq7vbwdm3jhrt2dav524 115 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 116 1 Ajani Ajani NNP work_ksthdbpq7vbwdm3jhrt2dav524 116 2 JA JA NNP work_ksthdbpq7vbwdm3jhrt2dav524 116 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 116 4 Ilson Ilson NNP work_ksthdbpq7vbwdm3jhrt2dav524 116 5 DH DH NNP work_ksthdbpq7vbwdm3jhrt2dav524 116 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 116 7 Daugherty Daugherty NNP work_ksthdbpq7vbwdm3jhrt2dav524 116 8 K K NNP work_ksthdbpq7vbwdm3jhrt2dav524 116 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 116 10 Pazdur Pazdur NNP work_ksthdbpq7vbwdm3jhrt2dav524 116 11 R R NNP work_ksthdbpq7vbwdm3jhrt2dav524 116 12 , , , work_ksthdbpq7vbwdm3jhrt2dav524 116 13 Lynch Lynch NNP work_ksthdbpq7vbwdm3jhrt2dav524 116 14 PM PM NNP work_ksthdbpq7vbwdm3jhrt2dav524 116 15 , , , work_ksthdbpq7vbwdm3jhrt2dav524 116 16 Kelsen Kelsen NNP work_ksthdbpq7vbwdm3jhrt2dav524 116 17 DP DP NNP work_ksthdbpq7vbwdm3jhrt2dav524 116 18 . . . work_ksthdbpq7vbwdm3jhrt2dav524 117 1 Activity activity NN work_ksthdbpq7vbwdm3jhrt2dav524 117 2 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 117 3 taxol taxol NN work_ksthdbpq7vbwdm3jhrt2dav524 117 4 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 117 5 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 117 6 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 117 7 squamous squamous JJ work_ksthdbpq7vbwdm3jhrt2dav524 117 8 cell cell NN work_ksthdbpq7vbwdm3jhrt2dav524 117 9 carcinoma carcinoma NN work_ksthdbpq7vbwdm3jhrt2dav524 117 10 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 117 11 adenocarcinoma adenocarcinoma NNP work_ksthdbpq7vbwdm3jhrt2dav524 117 12 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 117 13 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 117 14 esophagus esophagus NN work_ksthdbpq7vbwdm3jhrt2dav524 117 15 . . . work_ksthdbpq7vbwdm3jhrt2dav524 118 1 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 118 2 Natl Natl NNP work_ksthdbpq7vbwdm3jhrt2dav524 118 3 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 118 4 Inst Inst NNP work_ksthdbpq7vbwdm3jhrt2dav524 118 5 1994;86:1086–1091 1994;86:1086–1091 CD work_ksthdbpq7vbwdm3jhrt2dav524 118 6 . . . work_ksthdbpq7vbwdm3jhrt2dav524 119 1 10 10 CD work_ksthdbpq7vbwdm3jhrt2dav524 119 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 120 1 Ilson Ilson NNP work_ksthdbpq7vbwdm3jhrt2dav524 120 2 DH DH NNP work_ksthdbpq7vbwdm3jhrt2dav524 120 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 120 4 Wadleigh Wadleigh NNP work_ksthdbpq7vbwdm3jhrt2dav524 120 5 RG RG NNP work_ksthdbpq7vbwdm3jhrt2dav524 120 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 120 7 Leichman Leichman NNP work_ksthdbpq7vbwdm3jhrt2dav524 120 8 LP LP NNP work_ksthdbpq7vbwdm3jhrt2dav524 120 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 120 10 Kelsen Kelsen NNP work_ksthdbpq7vbwdm3jhrt2dav524 120 11 DP DP NNP work_ksthdbpq7vbwdm3jhrt2dav524 120 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 121 1 Paclitaxel Paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 121 2 given give VBN work_ksthdbpq7vbwdm3jhrt2dav524 121 3 by by IN work_ksthdbpq7vbwdm3jhrt2dav524 121 4 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 121 5 weekly weekly JJ work_ksthdbpq7vbwdm3jhrt2dav524 121 6 1-h 1-h CD work_ksthdbpq7vbwdm3jhrt2dav524 121 7 infusion infusion NN work_ksthdbpq7vbwdm3jhrt2dav524 121 8 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 121 9 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 121 10 esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 121 11 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 121 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 122 1 Ann Ann NNP work_ksthdbpq7vbwdm3jhrt2dav524 122 2 Oncol Oncol NNP work_ksthdbpq7vbwdm3jhrt2dav524 122 3 2007;18:898–902 2007;18:898–902 CD work_ksthdbpq7vbwdm3jhrt2dav524 122 4 . . . work_ksthdbpq7vbwdm3jhrt2dav524 123 1 11 11 CD work_ksthdbpq7vbwdm3jhrt2dav524 123 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 124 1 Van Van NNP work_ksthdbpq7vbwdm3jhrt2dav524 124 2 Cutsem Cutsem NNP work_ksthdbpq7vbwdm3jhrt2dav524 124 3 E E NNP work_ksthdbpq7vbwdm3jhrt2dav524 124 4 , , , work_ksthdbpq7vbwdm3jhrt2dav524 124 5 Moiseyenko Moiseyenko NNP work_ksthdbpq7vbwdm3jhrt2dav524 124 6 VM VM NNP work_ksthdbpq7vbwdm3jhrt2dav524 124 7 , , , work_ksthdbpq7vbwdm3jhrt2dav524 124 8 Tjulandin Tjulandin NNP work_ksthdbpq7vbwdm3jhrt2dav524 124 9 S S NNP work_ksthdbpq7vbwdm3jhrt2dav524 124 10 , , , work_ksthdbpq7vbwdm3jhrt2dav524 124 11 et et NNP work_ksthdbpq7vbwdm3jhrt2dav524 124 12 al al NNP work_ksthdbpq7vbwdm3jhrt2dav524 124 13 . . . work_ksthdbpq7vbwdm3jhrt2dav524 125 1 V325 V325 NNP work_ksthdbpq7vbwdm3jhrt2dav524 125 2 Study Study NNP work_ksthdbpq7vbwdm3jhrt2dav524 125 3 Group Group NNP work_ksthdbpq7vbwdm3jhrt2dav524 125 4 . . . work_ksthdbpq7vbwdm3jhrt2dav524 126 1 Phase phase NN work_ksthdbpq7vbwdm3jhrt2dav524 126 2 III iii CD work_ksthdbpq7vbwdm3jhrt2dav524 126 3 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 126 4 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 126 5 docetaxel docetaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 126 6 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 126 7 cisplatin cisplatin NNP work_ksthdbpq7vbwdm3jhrt2dav524 126 8 plus plus CC work_ksthdbpq7vbwdm3jhrt2dav524 126 9 fluorouracil fluorouracil NN work_ksthdbpq7vbwdm3jhrt2dav524 126 10 compared compare VBN work_ksthdbpq7vbwdm3jhrt2dav524 126 11 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 126 12 cisplatin cisplatin NN work_ksthdbpq7vbwdm3jhrt2dav524 126 13 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 126 14 fluorouracil fluorouracil NN work_ksthdbpq7vbwdm3jhrt2dav524 126 15 as as IN work_ksthdbpq7vbwdm3jhrt2dav524 126 16 first first JJ work_ksthdbpq7vbwdm3jhrt2dav524 126 17 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 126 18 line line NN work_ksthdbpq7vbwdm3jhrt2dav524 126 19 therapy therapy NN work_ksthdbpq7vbwdm3jhrt2dav524 126 20 for for IN work_ksthdbpq7vbwdm3jhrt2dav524 126 21 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 126 22 gastric gastric JJ work_ksthdbpq7vbwdm3jhrt2dav524 126 23 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 126 24 : : : work_ksthdbpq7vbwdm3jhrt2dav524 126 25 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 126 26 report report NN work_ksthdbpq7vbwdm3jhrt2dav524 126 27 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 126 28 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 126 29 V325 V325 NNP work_ksthdbpq7vbwdm3jhrt2dav524 126 30 Study Study NNP work_ksthdbpq7vbwdm3jhrt2dav524 126 31 Group Group NNP work_ksthdbpq7vbwdm3jhrt2dav524 126 32 . . . work_ksthdbpq7vbwdm3jhrt2dav524 127 1 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 127 2 Clin Clin NNP work_ksthdbpq7vbwdm3jhrt2dav524 127 3 Oncol Oncol NNP work_ksthdbpq7vbwdm3jhrt2dav524 127 4 2006;24:4991–4997 2006;24:4991–4997 CD work_ksthdbpq7vbwdm3jhrt2dav524 127 5 . . . work_ksthdbpq7vbwdm3jhrt2dav524 128 1 12 12 CD work_ksthdbpq7vbwdm3jhrt2dav524 128 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 129 1 Kaechele Kaechele NNP work_ksthdbpq7vbwdm3jhrt2dav524 129 2 V V NNP work_ksthdbpq7vbwdm3jhrt2dav524 129 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 129 4 Moehler Moehler NNP work_ksthdbpq7vbwdm3jhrt2dav524 129 5 M M NNP work_ksthdbpq7vbwdm3jhrt2dav524 129 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 129 7 Lutz Lutz NNP work_ksthdbpq7vbwdm3jhrt2dav524 129 8 MP MP NNP work_ksthdbpq7vbwdm3jhrt2dav524 129 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 129 10 et et NNP work_ksthdbpq7vbwdm3jhrt2dav524 129 11 al al NNP work_ksthdbpq7vbwdm3jhrt2dav524 129 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 130 1 A a DT work_ksthdbpq7vbwdm3jhrt2dav524 130 2 phase phase NN work_ksthdbpq7vbwdm3jhrt2dav524 130 3 I I NNP work_ksthdbpq7vbwdm3jhrt2dav524 130 4 / / SYM work_ksthdbpq7vbwdm3jhrt2dav524 130 5 II II NNP work_ksthdbpq7vbwdm3jhrt2dav524 130 6 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 130 7 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 130 8 oxaliplatin oxaliplatin NN work_ksthdbpq7vbwdm3jhrt2dav524 130 9 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 130 10 paclitaxel paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 130 11 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 130 12 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 130 13 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 130 14 non non JJ work_ksthdbpq7vbwdm3jhrt2dav524 130 15 - - JJ work_ksthdbpq7vbwdm3jhrt2dav524 130 16 resectable resectable JJ work_ksthdbpq7vbwdm3jhrt2dav524 130 17 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 130 18 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 130 19 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 130 20 oesophagus oesophagus NN work_ksthdbpq7vbwdm3jhrt2dav524 130 21 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 130 22 adenocarcinoma adenocarcinoma NNP work_ksthdbpq7vbwdm3jhrt2dav524 130 23 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 130 24 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 130 25 gastro gastro JJ work_ksthdbpq7vbwdm3jhrt2dav524 130 26 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 130 27 oesophageal oesophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 130 28 junction junction NN work_ksthdbpq7vbwdm3jhrt2dav524 130 29 : : : work_ksthdbpq7vbwdm3jhrt2dav524 130 30 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 130 31 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 130 32 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 130 33 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 130 34 Arbeitsgemeinschaft Arbeitsgemeinschaft NNP work_ksthdbpq7vbwdm3jhrt2dav524 130 35 Internistische Internistische NNP work_ksthdbpq7vbwdm3jhrt2dav524 130 36 onkologie onkologie NNP work_ksthdbpq7vbwdm3jhrt2dav524 130 37 . . . work_ksthdbpq7vbwdm3jhrt2dav524 131 1 Cancer Cancer NNP work_ksthdbpq7vbwdm3jhrt2dav524 131 2 Chemother Chemother NNP work_ksthdbpq7vbwdm3jhrt2dav524 131 3 Pharmacol Pharmacol NNP work_ksthdbpq7vbwdm3jhrt2dav524 131 4 2010;66:191–195 2010;66:191–195 CD work_ksthdbpq7vbwdm3jhrt2dav524 131 5 . . . work_ksthdbpq7vbwdm3jhrt2dav524 132 1 13 13 CD work_ksthdbpq7vbwdm3jhrt2dav524 132 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 133 1 Shah Shah NNP work_ksthdbpq7vbwdm3jhrt2dav524 133 2 MA MA NNP work_ksthdbpq7vbwdm3jhrt2dav524 133 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 133 4 Ramanathan Ramanathan NNP work_ksthdbpq7vbwdm3jhrt2dav524 133 5 RK RK NNP work_ksthdbpq7vbwdm3jhrt2dav524 133 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 133 7 Ilson Ilson NNP work_ksthdbpq7vbwdm3jhrt2dav524 133 8 DH DH NNP work_ksthdbpq7vbwdm3jhrt2dav524 133 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 133 10 et et NNP work_ksthdbpq7vbwdm3jhrt2dav524 133 11 al al NNP work_ksthdbpq7vbwdm3jhrt2dav524 133 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 134 1 Multicenter multicenter JJ work_ksthdbpq7vbwdm3jhrt2dav524 134 2 phase phase NN work_ksthdbpq7vbwdm3jhrt2dav524 134 3 II ii CD work_ksthdbpq7vbwdm3jhrt2dav524 134 4 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 134 5 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 134 6 irinotecan irinotecan NNP work_ksthdbpq7vbwdm3jhrt2dav524 134 7 , , , work_ksthdbpq7vbwdm3jhrt2dav524 134 8 cisplatin cisplatin NN work_ksthdbpq7vbwdm3jhrt2dav524 134 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 134 10 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 134 11 bevacizumab bevacizumab NNS work_ksthdbpq7vbwdm3jhrt2dav524 134 12 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 134 13 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 134 14 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 134 15 metastatic metastatic JJ work_ksthdbpq7vbwdm3jhrt2dav524 134 16 gastric gastric JJ work_ksthdbpq7vbwdm3jhrt2dav524 134 17 or or CC work_ksthdbpq7vbwdm3jhrt2dav524 134 18 gastroesophageal gastroesophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 134 19 junction junction NN work_ksthdbpq7vbwdm3jhrt2dav524 134 20 adenocarcinoma adenocarcinoma NNP work_ksthdbpq7vbwdm3jhrt2dav524 134 21 . . . work_ksthdbpq7vbwdm3jhrt2dav524 135 1 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 135 2 Clin Clin NNP work_ksthdbpq7vbwdm3jhrt2dav524 135 3 Oncol Oncol NNP work_ksthdbpq7vbwdm3jhrt2dav524 135 4 2006;24:5201–5206 2006;24:5201–5206 CD work_ksthdbpq7vbwdm3jhrt2dav524 135 5 . . . work_ksthdbpq7vbwdm3jhrt2dav524 136 1 14 14 CD work_ksthdbpq7vbwdm3jhrt2dav524 136 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 137 1 Shah Shah NNP work_ksthdbpq7vbwdm3jhrt2dav524 137 2 MA MA NNP work_ksthdbpq7vbwdm3jhrt2dav524 137 3 , , , work_ksthdbpq7vbwdm3jhrt2dav524 137 4 Jhawer Jhawer NNP work_ksthdbpq7vbwdm3jhrt2dav524 137 5 M M NNP work_ksthdbpq7vbwdm3jhrt2dav524 137 6 , , , work_ksthdbpq7vbwdm3jhrt2dav524 137 7 Ilson Ilson NNP work_ksthdbpq7vbwdm3jhrt2dav524 137 8 DH DH NNP work_ksthdbpq7vbwdm3jhrt2dav524 137 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 137 10 et et NNP work_ksthdbpq7vbwdm3jhrt2dav524 137 11 al al NNP work_ksthdbpq7vbwdm3jhrt2dav524 137 12 . . . work_ksthdbpq7vbwdm3jhrt2dav524 138 1 Phase phase NN work_ksthdbpq7vbwdm3jhrt2dav524 138 2 II ii CD work_ksthdbpq7vbwdm3jhrt2dav524 138 3 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 138 4 of of IN work_ksthdbpq7vbwdm3jhrt2dav524 138 5 modified modified NNP work_ksthdbpq7vbwdm3jhrt2dav524 138 6 docetaxel docetaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 138 7 , , , work_ksthdbpq7vbwdm3jhrt2dav524 138 8 cisplatin cisplatin NNP work_ksthdbpq7vbwdm3jhrt2dav524 138 9 , , , work_ksthdbpq7vbwdm3jhrt2dav524 138 10 and and CC work_ksthdbpq7vbwdm3jhrt2dav524 138 11 fluorouracil fluorouracil NN work_ksthdbpq7vbwdm3jhrt2dav524 138 12 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 138 13 bevacizumab bevacizumab NNS work_ksthdbpq7vbwdm3jhrt2dav524 138 14 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 138 15 patients patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 138 16 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 138 17 metastatic metastatic JJ work_ksthdbpq7vbwdm3jhrt2dav524 138 18 gastroesophageal gastroesophageal NN work_ksthdbpq7vbwdm3jhrt2dav524 138 19 adenocarcinoma adenocarcinoma NN work_ksthdbpq7vbwdm3jhrt2dav524 138 20 . . . work_ksthdbpq7vbwdm3jhrt2dav524 139 1 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 139 2 Clin Clin NNP work_ksthdbpq7vbwdm3jhrt2dav524 139 3 Oncol Oncol NNP work_ksthdbpq7vbwdm3jhrt2dav524 139 4 2011;29:868–874 2011;29:868–874 CD work_ksthdbpq7vbwdm3jhrt2dav524 139 5 . . . work_ksthdbpq7vbwdm3jhrt2dav524 140 1 15 15 CD work_ksthdbpq7vbwdm3jhrt2dav524 140 2 . . . work_ksthdbpq7vbwdm3jhrt2dav524 140 3 ohtsu ohtsu NNP work_ksthdbpq7vbwdm3jhrt2dav524 140 4 A A NNP work_ksthdbpq7vbwdm3jhrt2dav524 140 5 , , , work_ksthdbpq7vbwdm3jhrt2dav524 140 6 Shah Shah NNP work_ksthdbpq7vbwdm3jhrt2dav524 140 7 MA MA NNP work_ksthdbpq7vbwdm3jhrt2dav524 140 8 , , , work_ksthdbpq7vbwdm3jhrt2dav524 140 9 Van Van NNP work_ksthdbpq7vbwdm3jhrt2dav524 140 10 Cutsem Cutsem NNP work_ksthdbpq7vbwdm3jhrt2dav524 140 11 E E NNP work_ksthdbpq7vbwdm3jhrt2dav524 140 12 , , , work_ksthdbpq7vbwdm3jhrt2dav524 140 13 et et NNP work_ksthdbpq7vbwdm3jhrt2dav524 140 14 al al NNP work_ksthdbpq7vbwdm3jhrt2dav524 140 15 . . . work_ksthdbpq7vbwdm3jhrt2dav524 141 1 Bevacizumab Bevacizumab NNS work_ksthdbpq7vbwdm3jhrt2dav524 141 2 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 141 3 combination combination NN work_ksthdbpq7vbwdm3jhrt2dav524 141 4 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 141 5 chemotherapy chemotherapy NN work_ksthdbpq7vbwdm3jhrt2dav524 141 6 as as IN work_ksthdbpq7vbwdm3jhrt2dav524 141 7 first first JJ work_ksthdbpq7vbwdm3jhrt2dav524 141 8 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 141 9 line line NN work_ksthdbpq7vbwdm3jhrt2dav524 141 10 therapy therapy NN work_ksthdbpq7vbwdm3jhrt2dav524 141 11 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 141 12 advanced advanced JJ work_ksthdbpq7vbwdm3jhrt2dav524 141 13 gastric gastric JJ work_ksthdbpq7vbwdm3jhrt2dav524 141 14 cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 141 15 : : : work_ksthdbpq7vbwdm3jhrt2dav524 141 16 a a DT work_ksthdbpq7vbwdm3jhrt2dav524 141 17 randomized randomized JJ work_ksthdbpq7vbwdm3jhrt2dav524 141 18 , , , work_ksthdbpq7vbwdm3jhrt2dav524 141 19 double double JJ work_ksthdbpq7vbwdm3jhrt2dav524 141 20 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 141 21 blind blind JJ work_ksthdbpq7vbwdm3jhrt2dav524 141 22 , , , work_ksthdbpq7vbwdm3jhrt2dav524 141 23 placebo placebo NN work_ksthdbpq7vbwdm3jhrt2dav524 141 24 - - HYPH work_ksthdbpq7vbwdm3jhrt2dav524 141 25 controlled control VBN work_ksthdbpq7vbwdm3jhrt2dav524 141 26 phase phase NN work_ksthdbpq7vbwdm3jhrt2dav524 141 27 III iii CD work_ksthdbpq7vbwdm3jhrt2dav524 141 28 study study NN work_ksthdbpq7vbwdm3jhrt2dav524 141 29 . . . work_ksthdbpq7vbwdm3jhrt2dav524 142 1 J J NNP work_ksthdbpq7vbwdm3jhrt2dav524 142 2 Clin Clin NNP work_ksthdbpq7vbwdm3jhrt2dav524 142 3 Oncol Oncol NNP work_ksthdbpq7vbwdm3jhrt2dav524 142 4 2011;29:3968–3976 2011;29:3968–3976 CD work_ksthdbpq7vbwdm3jhrt2dav524 142 5 . . . work_ksthdbpq7vbwdm3jhrt2dav524 143 1 Sunitinib Sunitinib NNP work_ksthdbpq7vbwdm3jhrt2dav524 143 2 Plus Plus NNP work_ksthdbpq7vbwdm3jhrt2dav524 143 3 Paclitaxel Paclitaxel NNP work_ksthdbpq7vbwdm3jhrt2dav524 143 4 in in IN work_ksthdbpq7vbwdm3jhrt2dav524 143 5 Patients Patients NNPS work_ksthdbpq7vbwdm3jhrt2dav524 143 6 with with IN work_ksthdbpq7vbwdm3jhrt2dav524 143 7 Advanced Advanced NNP work_ksthdbpq7vbwdm3jhrt2dav524 143 8 Esophageal esophageal JJ work_ksthdbpq7vbwdm3jhrt2dav524 143 9 Cancer cancer NN work_ksthdbpq7vbwdm3jhrt2dav524 143 10 : : : work_ksthdbpq7vbwdm3jhrt2dav524 143 11 A a DT work_ksthdbpq7vbwdm3jhrt2dav524 143 12 Phase Phase NNP work_ksthdbpq7vbwdm3jhrt2dav524 143 13 II II NNP work_ksthdbpq7vbwdm3jhrt2dav524 143 14 Study study NN work_ksthdbpq7vbwdm3jhrt2dav524 143 15 from from IN work_ksthdbpq7vbwdm3jhrt2dav524 143 16 the the DT work_ksthdbpq7vbwdm3jhrt2dav524 143 17 Hoosier Hoosier NNP work_ksthdbpq7vbwdm3jhrt2dav524 143 18 Oncology Oncology NNP work_ksthdbpq7vbwdm3jhrt2dav524 143 19 Group Group NNP work_ksthdbpq7vbwdm3jhrt2dav524 143 20 PATIENTS patient NNS work_ksthdbpq7vbwdm3jhrt2dav524 143 21 AND and CC work_ksthdbpq7vbwdm3jhrt2dav524 143 22 METHODS methods JJ work_ksthdbpq7vbwdm3jhrt2dav524 143 23 RESULTS results NN work_ksthdbpq7vbwdm3jhrt2dav524 143 24 DISCUSSION discussion NN work_ksthdbpq7vbwdm3jhrt2dav524 143 25 REFERENCES reference NNS